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Abstract 
Retroviral compatibility with diverse glycoproteins has been known and identified 
through the course of several studies. However, molecular mechanisms of glycoprotein 
acquisition are poorly defined. Glycoproteins are acquired by the virus as it buds out of 
the cell at the plasma membrane. Budding of retroviruses involves multilple interactions 
between viral and cellular proteins and a mature viral particle is the consummation of a 
regulated and a sequential process. Currently there are no drugs to target the assembly 
step of retrovirus.  
 In the series of studies outlined here, we outline a physical factor, Vpu that 
contributes to glycoprotein exclusion from HIV particles. Using a model Vpu target, 
Gibbon ape Leukemia Virus (GaLV) Env, we have deduced the characteristics of a 
protein that is targeted by Vpu through its cytoplasmic tail domain (CTD). This unique 
observation of Vpu modulating the GaLV Env CTD allowed us to compare the two 
modes of Vpu mediated protein modulation- CTD mediated and membrane spanning 
domain (MSD) mediated.  
 Subsequently, we studied the contribution of MSD hydrophobicity to Env 
recruitment to viral budding sites. Curiously, although hydrophobicity of MSD did not 
dictate Env recruitment, the helicity changes as a result of our mutations resulted in 
observation of the Env fusogenicity.  
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I. Introduction 
A virus as a physical and functional entity requires the close co-operation of 
several cellular and viral proteins. The genome and the structural proteins assemble 
specifically with other viral components from the same or related viruses. In the case of 
enveloped viruses, it is known that foreign glycoproteins can assemble with different 
viral cores to produce infectious particles. Such a property is of tremendous interest in the 
field of gene therapy. Acquisition of foreign glycoproteins in addition to the native viral 
glycoproteins provides an opportunity to target different cells and tissues using similar 
viral vectors. Targeted gene delivery and specific regulation of genes in a tissue- specific 
manner would pave way for curing congenital diseases and certain infectious diseases in 
the long run. In particular, retroviruses have been used in such a context to cure patients 
with severe combined immunodeficiency (SCID). Foreign glycoproteins have been 
incorporated into replication incompetent retroviral vectors in order to achieve gene 
transfer to cells that are not targeted by the viruses in the natural course of infection. Such 
a tool needs to be understood completely, and the individual components have to be 
optimized, so that safe, effective and efficient gene delivery can be achieved. Retroviral 
vectors, having been clinically proven and well studied, provide an excellent model to 
undertake studies of vector optimization. Several components of retroviruses have been 
characterized, and diverse retroviral vectors for routine use in different applications have 
been developed. However, the mechanism of incorporation of glycoproteins into 
retroviruses is not completely understood.  
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Retroviruses 
A retrovirus is an enveloped single stranded, dimeric RNA virus. They use the 
enzyme Reverse Transcriptase (RT) to produce a dsDNA version of the RNA genome 
and also integrate into the host cell genome using the Integrase (IN) protein. A common 
feature of the retroviruses is the presence of Gag, Pol and Envelope (Env) genes (Figure 
1-1).Within the retroviral family, there are Alpha-, Beta-, Gamma-, Delta-, Epsilon-, 
Lenti- and Spuma- retroviruses (Figure 1-2). Gag is the structural protein, while Pol 
provides enzymatic functions. Env produces the surface glycoprotein that helps in 
targeting the virus to a specific cell type. The enzyme RT allows reverse transcription of 
the viral genome and is the defining characteristic of retroviruses. Retroviruses are 
integrated into the host cell genome at the end of an infection process. Para-retroviruses 
are a family of viruses that encode RT and reverse transcribe their genome, but do not 
integrate into the host cell genome. Simple retroviruses like the Alpha, Beta, Gamma, 
Epsilon sub families are made up of only the aforementioned three basic genes, whereas 
complex retroviruses like the Lenti, Delta and Spuma retroviruses have accessory 
proteins that help in viral pathogenesis (Figure 1-3). The accessory proteins provide vital 
functions and help in replication and/ or pathogenecity of virus. While not all accessory 
proteins are essential for replication of the respective virus, some of them are 
instrumental in the virus overcoming host restriction factors.  
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Figure 1-1: Retroviral genome schematic and structure of a retrovirus 
Retroviral genome encodes for Gag, Pol and Env proteins with the terminal 
repeats(R) and is common to all retroviruses. The genomic RNA is capped on its 5’ end 
and has a poly-A tail on its 3’ end, just like cellular mRNA. Other features in the RNA 
genome are shown; PBS-Primer binding site; PPT-Poly purine tract; Ψ-Packaging 
element. Untranslated 5’ and 3’ regions are marked as U5 and U3 respectively. Structure 
of a mature retrovirus is also shown. Image indicates the structural proteins from Gag, 
Functional enzymes from Pol, Envelope proteins as hetrodimers and the presence of 
dimeric RNA.  Image from Hubpages (http://enni82.hubpages.com/hub/Overview-of-
Retrovirus-Life-Cycle#) 
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Figure 1-1: Retroviral genome schematic and structure of a retrovirus 
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Figure 1-2: Phylogeny of retroviruses 
 Unrooted phylogenetic tree depicting the various retroviral sub-families are 
shown. The distinction between simple and complex retroviruses is made on the basis of 
absence or presence of accessory proteins. Some viruses belonging to the different sub-
families are indicated. Superscript red stars indicate simple retroviruses. Image from 
(233). 
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Figure 1-2: Phylogeny of retroviruses 
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Figure 1-3: Genetic organization of prototypic retroviruses 
 Figure shows the different genes encoded by the genomes of the indicated viruses, 
representing all the classes of retroviruses shown in Figure 1-2. Simple retroviruses 
encode only Gag, Pol and Env. Complex retroviruses encode other accessory proteins in 
its genome. Image adapted from (286). 
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Figure 1-3: Genetic organization of prototypic retroviruses 
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Retroviral Proteins and Genome 
Among retroviruses, HIV-1 is very well studied and characterized. HIV-1 Gag is 
produced as a single 55 kDa protein encompassing the N-terminal Matrix (MA), Capsid 
(CA) and C-terminal Nucleocapsid (NC) domains. Gag acts as the structural component 
of the virus. In all retroviruses, the N- terminal MA is post-translationally myristoylated 
at the glycine in position 2. Myristoylation is critical for membrane binding (228). HIV-1 
MA possesses a PIP2 (Phosphatidylinositol-4, 5-bisphosphate) recognition motif that also 
sereves to anchor the protein to the membrane by interaction with PIP2. MA can also 
bind to nucleic acids and may determine the binding of MA to the membrane. A highly 
basic region (HBR) in the MA composed of several lysines helps bind the MA to the 
negatively charged lipid head groups in the membrane (54, 105). MA may also bind to 
nucleic acids to prevent non-specific binding to lipid head groups (7). Typical retroviral 
structures are made possible by CA (6).  HIV-1 CA has two domains-N terminal domain 
(NTD) and C terminal domain (CTD) that are joined by a flexible linker. NTD forms 
hexameric and pentameric rings, while the CTD forms homodimers that allows the capsid 
to assume the core structure (18). The C- terminal NC domain recognizes and interacts 
with the viral genomic RNA during viral assembly. Also, NC provides crucial 
interactions among HIV-1 Gag molecules in the immature particle. Presence of Gag 
alone can promote the production of virus like particles (VLP), in the presence or absence 
of other cellular factors. Gag is also known to be phosphorylated, although the functional 
relevance of this modification is not understood yet (4, 18, 77, 272).  
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Generally in retroviruses, the Gag ORF is transcribed and translated into the Gag 
protein only. At times, a ribosomal frameshift occurs, resulting in the translation of Gag-
Pol (277). In the case of Murine Leukemia Virus (MLV), the Gag-Pol is produced by 
read-through or suppression of the stop codon. In Beta- and Delta-retroviruses, protease 
is encoded in an ORF independent of Gag and Pol. In such cases, two frameshifting 
events occur, to ensure the production of Gag-Pro-Pol. With Spumaviruses, the Pro-Pol is 
produced independently of Gag (232) (Figure 1-4).  
 
The Pol encodes the Protease (PR), Reverse transcriptase (RT), and Integrase (IN) 
proteins. Pol is the functional enzymatic unit of the virus. PR cleaves itself out of the Pol 
protein and proteolytically releases the individual structural and functional domains from 
the Gag and Pol proteins. PR activation happens at or immediately after the point of viral 
release from the host cell and this process is termed as viral maturation. RT helps in 
converting the genomic RNA into cDNA. IN helps in integrating the viral dsDNA, 
produced by RT, into the target cell genome (286).  
 
The viral RNA genome is flanked by repeats (R), untranslated 3’ region (U3) 
preceding R at the 3’ end of genome and untranslated 5’ region (U5) succeeding R at the 
5’ end of the genome. In the integrated proviral DNA form, U3-R-U5 forms the long 
terminal repeats (LTR) at either end of the genome (Figure 1-5). The LTRs possess 
promoter activity and help in transcription of the viral encoded between the two LTRs. 
Certain cis acting elements like the primer binding site (PBS), packaging element (Ψ), 
12 
 
dimerization inititation site (DIS) and poly purine tract (PPT) are absolutely required for 
producing infectious particles. Ψ is recognized by NC and determines packaging of the 
genome into the viral particle. Regardless of the genome size, a RNA dimer is packaged 
into the virus and genomic RNA dimers are created by interaction of RNA molecules at 
the DIS. The structure of the HIV-1 genomic RNA has recently been deduced (292) 
(Figure 1-6). In addition to the genomic RNA and the tRNA primer, cellular RNA is also 
packaged into a budding viral particle (286). 
 
Retroviral Env glycoproteins deck the surface of the virus. Env provides the 
functions of receptor recognition and fusion with host cell membrane. Env is produced 
from a spliced genomic RNA, which lacks Gag and Pol coding regions. Env is trimeric 
and is composed of heterodimers containing a surface subunit (SU) and a transmembrane 
subunit (TM) (Figure 1-7). The N-terminal portion of the SU dictates the binding of the 
virus to a specific surface receptor protein on the target cell. The SU is linked to the TM 
by covalent or non-covalent interactions. SU and TM are held together by an inter- 
subunit disulphide bond in the case of alpha-, gamma-, and delta-retroviruses (80, 122, 
152, 208, 223, 225); and non-covalently associated in the case of lenti- and beta- 
retroviruses (102, 143). Binding of the SU to its cognate receptor triggers a 
conformational change in the Env, leading to coreceptor binding or the exposure of the 
fusion peptide at the N-terminus of TM, which acts like a class I fusion protein (108, 
286). 
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Env undergoes multiple changes during its biogenesis and trafficking in the virion 
producing cell. The Env is produced as a type I transmembrane precursor and upon signal 
peptide recognition, is translated from ER bound ribosomes (Figure 1-8). The signal 
peptide is co-translationally cleaved. The Env is also glycosylated co-translationally. N-
linked glycosylation occurs on the asparagine in the canonical N-X-S/T motif, where X is 
any amino acid but proline or glycine. O-linked glycosylation also occurs on the Env. 
The range of glycosylation varies in different retroviral Envs and within a host due to the 
high mutation rate of retroviruses several quasispecies with different sites of 
glycosylation are present. Env trimerizes in the ER and this process is thought to be the 
rate limiting step in Env synthesis (108, 286). Env glycoproteins with similar 
ectodomains may heterotrimerize and this has been demonstrated with HIV-1and HIV-2 
Env (41). Post ER, the precursor undergoes furin cleavage to produce the mature Env 
possessing the SU and TM domains. The ectodomain of TM and the SU are then linked 
covalently by cysteine disulphide linkage(s) or non-covalently. The furin cleavage is 
essential for fusogenicity and infectivity with Env (83-84, 168, 184). With MLV Env, 
when cleavage is blocked higher molecular weight species of Env have been observed, 
and that may represent an intermediate in the biogenetic pathway(84).  
 
Lentiviral glycoproteins have a very long cytoplasmic tail domain (CTD) 
compared to those of other retroviruses (Figure 1-9). The length of the CTD in 
lentiviruses may represent an evolutionary significance (227). Such an idea is supported 
by the fact that, truncation of the CTD in causes multiple changes in Env trafficking, 
virus incorporation, fusogenicity, cell surface expression etc. in a cell type dependent 
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manner (58, 227). In the specific case of Feline immunodeficiency virus (FIV) Env, 
truncation of the entire CTD enhances incorporation into viral particles, while partial 
truncations in the CTD affect fusogenecity and surface expression (40). Tyrosine and di-
leucine motifs in HIV-1 Env CTD are thought to interact with adaptor-protein complexes, 
that also interact with the respective Gag proteins (14, 67). A combination of such 
trafficking motifs allows an optimal level of HIV-1 Env surface expression that prevents 
a high level of immune response and at the same time allows efficient HIV-1 virion 
production. The YxxL tyrosine motif is also known to target HIV-1 Env to the cellular 
basolateral surface in polarized epithelial cells, cell-cell transmission in T-cells and 
efficient particle infectivity (64, 161-162). The Yxxɸ tyrosine motif (where ɸ is any 
hydrophobic amino acid) in MLV Env or HTLV Env also dictates trafficking, as 
mutations within this motif affects Env distribution (64). 
 
Retroviral glycoproteins are palmitoylated or possess consensus sequences 
recognized by the cellular palmitoylation machinery (101, 204, 307). Palmitic acid is a 
fatty acid modification of membrane bound proteins, usually by a thio-ester linkage to 
cysteine residues at or close to the membrane. The hydrophobicity of the palimitic acid 
helps the protein bind to the membrane. Mutation of palmitoylation sites in HIV-1 Env, 
MLV Env or RSV Env results in decreased association with lipid rafts, endocytosis, 
virion incorporation, surface expression, but no apparent decrease in fusogenicity (20, 
158, 204, 242). Palmitate thus provides multiple benefits to the Env proteins- in terms of 
incorporation by virtue of surface expression and association with lipid rafts, where Gag 
has been shown to assemble.  
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Beta- and Gamma-retroviral Envs possess an R-peptide in their C-terminus (32, 
100). The R-peptide is cleaved by the viral protease to activate the Env for fusion. 
Presence of R-peptide is fusion inhibiting, as shown with the Influenza virus 
Hemaglutinin protein (157). Env fusogenicity is dependent on receptor binding followed 
by conformational changes in the heterodimeric Env protein (59, 165, 290). 
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Figure 1-4: Gag, Pol translational mechanisms 
 Expression of Gag and Gag-Pol occurs from translation of the same mRNA. 
Translation past the 3′end of the Gag-coding sequence results in the synthesis of Gag-Pol 
fusion proteins. Gag-Pol translation occurs by ribosome framseshifting (fs), or 
suppression of stop codon (is). Organization of the various retroviral genomes depicted 
shows the production of Gag-Pol in the different retroviruses (232).  
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Figure 1-4: Gag, Pol translational mechanisms 
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Figure 1-5: Host cell integrated, proviral DNA and genomic RNA 
 Figure indicates the organization of the DNA form of the integrated provirus, 
showing the different genes encoded within the genome. The DNA form is flanked by 
long terminal repeats (LTRs) characterized by the U3-R-U5 on either end of the genome. 
The RNA form shows the transcribed genes with a splicing intermediate, that allows 
translation of viral proteins in the infected cells. The RNA is similar to cellular mRNA 
and differs from the proviral DNA form by the absence of LTRs. Image from (286). 
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Figure 1-5: Host cell integrated, proviral DNA and genomic RNA 
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Figure 1-6: Structure of HIV-1 RNA 
Figure depicts the structure of HIV-1 NL4-3 RNA as determined by Selective 2’-
hydroxyl acylation analyzed by primer extension (SHAPE). The various features of the 
genomic RNA are labeled (292). 
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Figure 1-6: Structure of HIV-1 RNA 
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Figure 1-7: Cartoon representation of Env trimer 
 Env consists of extracellular SU subunit and a transmembrane TM subunit. 
Various features of an Env are shown in this figure. RBD- Receptor binding domain; 
PRR- Proline rich region; HR- Heptad repeat; H8- Histidine 8; FP- Fusion peptide. Image 
adapted from (265). 
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Figure 1-7: Cartoon representation of Env trimer 
 
 
 
 
 
 
 
 
 
24 
 
Figure 1-8: Env biogenesis and trafficking 
 Env is synthesized in the ER, where the signal peptide is cleaved and Env 
trimerizes. In the Golgi, Env is cleaved by furin or furin like protease into its constituent 
subunits. Env is then trafficked to the plasma membrane, where it gets incorporated into 
viral particles. Image from (273). 
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Figure 1-8: Env biogenesis and trafficking 
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Figure 1-9: Cytoplasmic tail length varies in different retroviruses 
 Lentiviruses have much longer CTDs than other retroviruses. CTD influences 
incorporation of Env into retroviral particles and CTD lengths seem to be evolutionarily 
significant. Image from (227). 
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Figure 1-9: Cytoplasmic tail length varies in different retroviruses 
 
 
 
 
 
 
 
 
 
 
 
28 
 
Retroviral assembly 
 Assembly of an infectious retroviral particle requires that the RNA genome, Gag 
and Gag-Pol proteins and Env glycoproteins coalesce in the cell. Gag alone is capable of 
assembling into particles in cells and in vitro. To describe in broad terms, Gag interacts 
with genomic RNA and traffics the RNA to the membrane where other Gag moieties 
multimerize. This is followed by Env recruitment to the assembly site, resulting in 
budding of a complete virion with the help of other cellular factors (18, 232).  
 
 Retroviruses may assemble at the plasma membrane or in the cytoplasm as 
Intracellular Cytoplasmic A Particles (ICAPs). The former, termed as C-type assembly 
occurs by Gag multimerization at the plasma membrane and subsequent acquisition of 
glycoproteins prior to budding. The latter is termed as B/D type assembly and here Gag 
containing particles are formed in the cytoplasm, and the virions acquire the glycoprotein 
when they are trafficked to the membrane and exuded from the cell. Although distinct 
patterns of assembly exist, a single mutation in MPMV Gag switches the assembly 
phenotype from B/D type to a C-type assembly, indicating that assembly mechanisms 
might be similar (237). Many immature particles have been observed in the ER as 
Intracisternal A-type Particles (IAPs). These predominantly occur with endogenous 
retroviruses that encode defective components of Pol and Env (147) (Figure 1-10). While 
immature particles of all retroviruses have a spherical core with an electron-translucent 
center, mature particles have a specific morphology with an electron dense center and the 
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morphology is defined by the CA-CA interactions. CA cores have been shown to 
determine the size of the mature viral particles (6).  
 Gag is synthesized in the cytoplasm on free ribosomes. Multiple components in 
the virus interact sequentially to form an immature particle in the cell. Although the 
sequential order of the various interactions are not completely understood, retroviral 
assembly requires protein-protein, protein-RNA and protein-lipid interactions to produce 
an infectious particle. Using HIV-1 as a model, recently it has been shown that Gag 
interacts with the genomic RNA in the cytoplasm and forms lower order multimers in the 
cytoplasm, while higher order Gag multimers have been observed on membranes (149) 
(Figure 1-11). As mentioned earlier, Gag binding to membrane is strengthened by three 
different methods- (1) Interaction with the negatively charged lipid head groups through 
the HBR. (2) PIP2 interaction with MA on the inner leaflet of the membrane and (3) 
Myristate group based anchoring of MA to the lipid bilayer (34, 53, 61-62, 170, 197, 
205). Recent reports of Rous Sarcoma Virus (RSV) Gag have shown that PIP2 does not 
influence membrane association (44) and compensatory mutations in HIV-1 Gag have 
been identified in MA when PIP2 in the infected cells is depleted (192). In direct contrast 
to such reports, HIV and MLV particles are enriched in PIP2 (45). It is not clear whether 
PIP2 influences the site of viral budding at the plasma membrane, or alternatively, if Gag 
allows an enrichment of PIP2 at the viral budding site.  
 
The site of HIV-1 particle assembly is debated, with imaging studies showing the 
assembly process to occur on the inner leaflet of the plasma membrane (1-2, 111, 133) 
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(Figure 1-11). But, in certain cell types like macrophages, it has been shown to assemble 
in intracellular vesicles (63, 218). Later these vesicles were shown to be membrane 
invaginations that were continuous with the plasma membrane (19, 294). Spread of HIV-
1 infection occurs more efficiently in a cell-to-cell manner, through interfaces of cell 
contacts called virological synapses, than by infection of fresh cells by cell-free virus (37, 
127, 229, 258). Gag and Env coalesce at the virological synapse, in addition to other 
proteins like CD4, adhesion molecules etc (128, 229). MLV and HIV particles readily 
form the synapse, where Env receptor and other cell-cell interactions take place (185) 
(258) (123-126, 128, 315).  
 
 Lipid analysis of retroviral particles has shown the enrichment of lipid-raft 
associated lipds or lipids arranged in a lower mobility state in viral particles (221, 230-
231, 266-267). Further, HIV-1 envelope is enriched for cholesterol and sphingolipds, 
found in lipid ordered microdomains. Also, cholesterol depletion in virus producing cells 
or viruses interferes with viral release, structural stability of virus, and infectivity (9, 33, 
38-39, 90, 94). Cholesterol and other sphingolipids are found in higher concentrations in 
lipid- rafts, a lipid ordered microdomain, which has lower mobility of lipids within the 
raft region. Glycoproteins involved in signaling, phosphoinositides, etc. are enriched in 
the lipid rafts. Experimentally, lipid rafts are defined as detergent-insoluble membranes at 
4
o
C. Additionally, certain lipid-raft associated proteins have been reported to be 
incorporated to HIV-1 particles (202, 210) (245), while some non-raft proteins are 
excluded from viral particles (202). Gag association with drug resistant membranes 
supports the idea of HIV-1 budding from lipid rafts (66, 96, 106, 159, 202, 206-207, 
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222). At the moment, the role of lipid microdomains in the assembly and release of virus 
is not entirely clear, despite the multitude of studies performed on the lipid composition 
of viral particles and biochemical analysis of Lipid- Gag interaction (287-288). 
 
While membranes may have several different ‘microdomains’ containing different 
lipid or protein compositions, HIV-1 assembly and replication have been most associated 
with lipid rafts and Tetraspanin enriched microdomains (TEMs). Tetraspanins, as the 
name suggests, contain four membrane spanning domains and are usually palmitoylated. 
HIV-1 is enriched in certain tetraspanins when they are expressed in high quantities in an 
infected cell. Tetraspanins seem to regulate HIV-1 Env fusogenicity and they colocalize 
with ESCRT1 components, which have been shown to facilitate HIV-1 budding. 
However, tetraspanins do not enhance or affect the budding process itself (144, 171).  
  
The roles of lipids and tetraspanins in viral budding have not been clearly 
understood. Membranes are a fluidic body and the plausibility of static microdomains to 
which Gag binds is questionable. Although, it is entirely possible that Gag changes the 
local environment in the membrane.  Gag multimerization may affect lipid and protein 
distribution at the virion assembly site, which in turn determines the constitutents of the 
budded viral particle. Virion associated host cell proteins are largely dependent on the 
cell producing the virus. Some cellular factors maybe specific to certain cell types and 
they may influence protein recruitment to budding viral particles, while certain other 
proteins maybe abundant in certain cell types and hence may be incorporated in virions 
(210). 
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 In addition to Gag forming the viral particles, maturation of the budded virion 
requires the presence of PR and completion of the infection requires Pol. Covalent 
linkage of the Gag and Pol proteins ensures the recruitment of Pol into the Gag nucleated 
viral particles. However this translational linkage is not absolutely necessary, as 
accessory proteins like Vpr in HIV-1 is recruited to budding viruses, by virtue of its 
interaction with MA. Also, with spumaviruses, Pol protein is produced independent of 
Gag and is also incorporated efficiently into the viral particle. This suggests that although 
covalent linkage is a simple mechanism of protein incorporation in viral particles, the 
linkage is not absolutely essential. Many other cellular proteins are also incorporated into 
viral particles, by virtue of their abundance in the cytoplasm.  
 
HIV budding has been shown to be dependent on the ESCRT-I complex and 
recruitment of Tsg101 belonging to the ESCRT complex is a result of interaction with 
HIV-1 Gag PTAP motif, termed as the late domain. MLV, RSV, HTLV-I, MPMV Gags 
possess a PPXY late domain motif, that may indirectly activate the ESCRT complex and 
thus help viral egress. Late domain mediated viral release may interact directly or 
indirectly with components of the ESCRT protein complexes. Mutation of the late 
domain mutants results in an immature particle phenotype (25-26, 55, 89, 99, 136, 180, 
186, 216, 257, 301, 305, 309, 311). 
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Figure 1-10: Different patterns of retroviral particle assembly 
 B/D type of assembly occurs in intracellular locations, followed by trafficking of 
the particle to the plasma membrane where the Env is incorporated into particles. C-type 
assembly occurs on the inner leaflet of the plasma membrane, where Env trimers coalesce 
with the virion. Intracytoplasmic A-type particles (ICAPs) assemble in the lumen of ER. 
They remain unprocessed and without Env. Image from (232). 
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Figure 1-10: Different patterns of retroviral particle assembly 
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Figure 1-11: C-type assembly of HIV-1 particles 
 Lower order multimers of Gag in the cytoplasm traffic to the plasma membrane 
where, higher order multimers are formed. Lipid raft binding has been depicted in this 
cartoon. Env is recruited to viral budding sites and the virus buds, followed by maturation 
of virus. Image from (287). 
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Figure 1-11: C-type assembly of HIV-1 particles 
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Recruitment of Env to viral particles 
 Retroviruses have the ability to form infectious particles with foreign Env 
glycoproteins from different retroviruses and different viral families. This process is 
termed pseudotyping and it serves to change the tissue tropism of the respective viral 
particles (60, 121, 182, 214). Acquisition of the native Env may be a result of 
evolutionary selection and optimization. However, recruitment of cellular and foreign 
viral glycorproteins is surprising. Nonetheless, this provides a way of targeting similar 
vector particles to different tissues for application in gene therapy scenarios. While Gag 
is produced in the cytoplasm on free ribosomes, Env is produced on ER bound 
ribosomes. To be incorporated into virions, Env has to be trafficked to the membrane 
through which retroviral particles bud. The specific mechanisms of Env recruitment and 
trafficking are not clearly understood. All retroviral glycoproteins are produced as type I 
transmembrane proteins and later processed into a mature form, as mentioned earlier.  
 
  Some lentiviral glycoproteins exhibit incompatibility with non-native Gags, 
presumably due to steric incompatibility of Gag lattices with the long CTDs of the 
lentiviral Envs. With HIV-1 and SIV Env, the CTD has been shown to regulate viral 
replication, by either changing the site of budding in cells or by providing selective 
advantage for the virus in a cell dependent manner. In replication permissive cell lines, 
HIV-1 CTD Env is incorporated into viruses at close to normal levels. In peripheral 
blood mononuclear cells and monocyte derived macrophages, HIV-1 CTD Env is not 
incorporated into viruses efficiently and as a result these cell lines are non-permissive for 
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viral replication with CTD Env. The CTD truncation mutant by itself is processed well 
and is fusogenically active (5, 71, 86, 195, 295, 310). Although these differences among 
cell lines are not understood, it is clear that the CTD of HIV-1 Env dictates Env 
incorporation into virions (227). Conversely with SIV Env, CTD truncations 
spontaneously arise when passaged in human cells and results in better Env incorporation 
and higher fusogenicity. However, in Rhesus cells, SIV selects for Env with full length 
CTD. Such cell type dependence of the CTD of these Envs is not very well understood 
(42, 141-142). In the case of MLV Env, removal of the CTD does not prevent specific 
recruitment of Env to viral budding sites. However, in a competitive assay between HIV 
and MLV particles, the CTD dictates specific incorporation of Env into MLV particles 
(91, 168).  
 
 In MDCK cells, in the presence of HIV-1 Env, HIV viral assembly occurs on the 
basolateral surface and may be a direct result of enrichment of negatively charged 
phospholipid headgroups (64, 161-162). With rat neuronal cells, HIV-1 Env induces a 
redistribution of HIV Gag and MLV Env induces a redistribution of MLV Gag molecules 
(293). Also, MLV Env directs MLV Gag recruitment to viral budding sites in the 
virological synapse (315). These data indicate an Env directed assembly phenotype for 
retroviral particles. Further, non-native Envs are specifically incorporated into viral 
particles as shown with a correlative high-resolution imaging technique (131). MLV Env 
expression in the absence of Gag shows a random distribution on the surface of the cell. 
When MLV Env is expressed along with MLV Gag or HIV Gag, the Env on the cell 
surface is redistributed specifically around the viral budding sites (168). Collectively, 
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multiple studies on different Envs indicate a role of the CTD in recruitment to viral 
budding sites.  
 The tyrosine-sorting motifs in Env CTD play a role in Env directed virus 
assembly and pathogenesis in addition to regulating trafficking of Env. In polarized 
epithelial cells, the tyrosine motif determines basolateral targeting of Env and infectious 
viral budding. The tyrosine motif also allows the Env and Gag to coalesce at the 
virological synapse, helping cell-to-cell transmission of virus (64, 119, 161-162, 260). 
Another unique sorting motif found in the gammaretroviral RD114 Env causes 
incompatibility with SIV Gag. PACS-1, a cellular protein mimics SIV Gag in 
redistributing RD114 Env to endosomes by interaction with this acidic motif (27).  
 
 Another example of a cellular protein that mediates coalescence of HIV-1 Env 
with budding HIV virions is Tail Interacting Protein of 47kDa (TIP47), also known as 
Perilipin3. In the cell, TIP47 is implicated in lipid biogenesis and protein sorting to such 
lipids. TIP47 was reported to be a necessary connector between HIV MA and HIV Env 
CTD (17, 24, 163). Since then the role of TIP47 in Env recruitment has come into 
question with in vitro studies showing non-requirement of TIP47 for HIV MA and HIV 
Env CTD binding, and RNA mediated knockdown of TIP47 showing no change in 
infectivity, virion release and Env incorporation into HIV particles (47).  
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Retroviral Life Cycle 
The budding virion, having thus assembled and acquired Env glycoproteins, is an 
infectious unit that may now infect a new target cell and may proceed with its life cycle 
(Figure 1-12). The receptor binding and/or coreceptor binding is followed by fusion of 
the viral and target cell membranes with the help of a type I fusion mechanism involving 
the fusion peptide in the Env (120). The viral components are then released into the host 
cell. The mature gag composing the core contains the enzymatic components along with 
the viral RNA. Reverse transcription of the viral genome takes place in the cytoplasm of 
the target cell. The exact order of the early events in an infection is not clear, with the 
timing of reverse transcription, capsid uncoating and nuclear import of the viral genome 
unresolved. tRNA molecules from the virus producing cell usually prime cDNA synthesis 
in retroviruses and they bind to the viral genomic RNA at the PBS. Different RNA/DNA 
intermediates are produced during the viral cDNA production by RT. PPT helps in 
priming the second strand synthesis in the dsDNA. RNaseH domain of the RT degrades 
the RNA in the RNA-DNA duplex intermediates during cDNA synthesis (3) (Figure 1-
13). Reverse transcription can occur in the absence of the retroviral gene ORFs within the 
genome and this provides a basis for retroviral vectors.  
 
The pre-integration complex (PIC) containing viral and some cellular proteins is 
imported into the nucleus (as in the case of lentiviruses) or accesses the host cell genomic 
content during cell division, when the nuclear membrane breaks down. Specific target 
sequences in the host cell DNA are not required for integration. IN helps in integrating 
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the dsDNA into the target cell genome (226). The different viral proteins are synthesized 
in the infected cell and the proteins are trafficked to the budding site. Unspliced genomic 
RNA is also recruited to the viral budding site by an interaction with NC. Env 
glycoproteins then coalesce at the budding viral particle. The viruses are then budded out 
of the cell at which point the PR is activated, mediating the maturation of the virus (57).  
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Figure 1-12: Retroviral life cycle 
 Cell-free virus binds to the receptor on the target cell surface and fusion of host 
and viral membranes occur. The contents of the viral particles are released into the 
cytoplasm of the target cell and reverse transcription of the viral genome takes place. The 
viral dsDNA is translocated to the nucleus as a part of the PIC. IN helps in integration of 
the viral DNA into the host cell genome. Viral proteins are synthesized; genomic RNA 
and other viral proteins are trafficked to the plasma membrane where, the viruses 
assemble and bud. Image from NCI, Open access. 
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Figure 1-12: Retroviral life cycle 
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Figure 1-13: Process of reverse transcription 
 The different stages of reverse transcription of viral DNA are shown. Image from 
(3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45 
 
Figure 1-13: Process of reverse transcription 
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Retroviral Vectors 
The Gag-Pol and Env may be provided in trans to the genomic element to 
produce infectious viral particles. This allows for the retroviral genes between the LTR to 
be replaced with a target gene of interest, conserving the necessary cis acting elements. 
This also serves the purpose of providing a larger piece of DNA that can be inserted 
between the LTRs. Since vectors used in gene transfer have to be non- replicative, such 
separation of the individual components helps in creating an effective vector. In fact, 
during the production of viral vectors, the Gag, Pol and the Env genes are removed from 
the genome to prevent replicative spread of virus and viral particles are produced by co- 
transfection of the individual encoding constructs. Further, several refinements of the 
vectors have led to the advent of self inactivating lentiviral and retroviral vectors, 
carrying chimeric LTRs (11, 137). Retroviral vectors have been successfully used in a 
clinical setting to treat patients with severe combined immunodeficiency syndrome 
(SCID) (23, 87). Several improvements have been made with retroviral vectors and the 
latest series of self-inactivating vectors will go a long way in gene therapy treatment 
without further complication from replication competent retrovirus (RCR). While 
retroviral vectors maybe used for targeted gene delivery to dividing cells, lentiviral 
vectors provide the unique opportunity to target terminally divided cells.  
 
Env binds very specifically to its cognate receptor, and since different receptor 
proteins are expressed at different levels in various tissues, targeted gene delivery to 
different tissues cannot be achieved with the same vector. The vectors can be modified at 
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this juncture by providing a compatible Env from a different virus. The process by which 
viral particles of one type are produced with a glycoprotein from another virus is called 
pseudotyping and the viral particles so produced are called pseudotypes.  
 
 
 
Pseudotyping of retroviral particles 
Retroviral pseudotyping provides some obvious benefits in the targeted gene 
delivery module. On the one hand, viral tropism can be altered and the viral vector can be 
directed to different tissues and cell types that are not normally infected by the parent 
vector; On the other hand, use of lentiviral vectors with different Env proteins on the 
surface would enable gene delivery to different non- dividing cells, while other retroviral 
vectors can infect only dividing cells. Furthermore, stable integration and long term 
expression of any gene of interest can be achieved with retroviral vectors (11, 214).  
 
Pseudotyping has been achieved within the retroviral family and also between 
different viral families. For example, Human Immunodeficiency virus (HIV), a lentivirus, 
is compatible with glycoproteins from many families of viruses, including alpha-, beta-, 
gamma-, delta-, spuma-retroviruses and other lentiviruses in addition to glycoproteins 
from rhabdoviruses, filoviruses, togaviruses, arenaviruses, coronaviruses, flaviviruses, 
orthomyxoviruses, paramyxoviruses and baculoviruses (50, 60, 104, 121, 139-140, 148, 
150, 156, 160, 190, 193, 198, 214, 236, 312). The recruitment of native viral proteins to 
its budding sites in the cell maybe realized as a specific mechanism of viral survival. 
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Several lines of evidence point that native glycoproteins interact with the structural Gag 
protein. In the case of HIV, MA interacts with the cytoplasmic tail domain (CTD) of HIV 
Env and is required for incorporation of Env into viral particles (46, 194, 211). Also, the 
C-terminal 16 amino acids of MLV Env, termed the R-peptide, have been reported to be 
associated with the MLV viral core (10). Recruitment of a variety of foreign viral 
glycoproteins to viral egress sites, however, indicates a more generic property of viral 
envelope proteins.  MLV Env and the G- protein from Vesicular stomatitis virus (VSV) 
are compatible with Rous sarcoma virus (RSV) cores and HIV cores (132). Some cellular 
transmembrane proteins are also incorporated into viral particles, potentially due to the 
high local concentration or random distribution of these proteins at the general area of 
viral budding (210). The viral components that promote recruitment of foreign 
glycoproteins and the physical factors that drive the Env towards other viral budding sites 
are not known. Comparison of mechanisms of pseudotyping and native glycoprotein 
acquisition will provide details of Env incorporation into several different viral particles. 
 
Foreign Env acquisition by retroviral particles can be a result of passive and non-
specific or active and specific incorporation. Pseudotyping of retroviral particles and 
cellular glycoprotein incorporation into viral particles supports the notion of a passive 
process. Specific recruitment of certain Env glycoproteins may also exist- (1) Convergent 
trafficking to membrane microdomains; (2) Direct interactions between viral structural 
proteins and Env; (3) Interaction with cellular proteins mediating coalescence. Several 
examples of specific recruitment of Env to particular viral particles have been reported. 
However, the molecular mechanisms of Env recruitment are not known and an over-
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arching mechanism of glycoprotein recruitment to viral particle has not yet been 
postulated.  
 
Pseudotyping of HIV particles with MLV Env 
HIV is able to form infectious particles with the gammaretroviral MLV Env. By 
correlative SEM imaging, our lab has shown that MLV Env is recruited specifically to 
viral budding sites. Further, the CTD of MLV Env is not required for this specific 
recruitment (168). MLV Env possesses a fusion restricting R-peptide in its C-terminus 
that is removed by the viral protease during viral maturation. HIV PR is also able to 
cleave the MLV Env R-peptide, thus making the viral particle infectious (50, 91).  
 
The studies detailed in the following chapters outline mutational analyses that add 
to the understanding of physical factors favoring glycoprotein recruitment to viral 
budding sites. A gammaretroviral Env like MLV Env or GaLV Env has been used as a 
model to study glycoprotein recruitment. The following two chapter outline sequences 
and characteristics of a model Vpu target protein, the Gibbon ape Leukemia Virus 
(GaLV) Env, that dictate its exclusion from HIV-1 particles (113, 115). In the fourth 
chapter, details of a study consisting of mutational analysis of the CTD of Vpu that was 
performed to identify sequences in Vpu that prevented the trafficking of GaLV Env and 
Tetherin (an antiviral, interferon induced host cell glycoprotein) to HIV-1 budding sites is 
described (166). The fifth chapter describes the study of the hydrophobic patch of amino 
acids in the MLV Env membrane spanning domain (MSD) (114). This study yielded 
interesting information about Env fusogenicity.  
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II. SEQUENCES IN GIBBON APE LEUKEMIA VIRUS 
ENVELOPE THAT CONFER SENSITIVITY TO HIV-1 
ACCESSORY PROTEIN VPU 
 
Sanath Kumar Janaka, Tiffany Lucas, Marc C Johnson 
 
This work has been published in the Journal of Virology (115) 
 
Abstract: 
HIV-1 efficiently forms pseudotyped particles with many gammaretrovirus 
glycoproteins such as Friend murine leukemia virus (F-MLV) Env, but not with the 
related gibbon ape leukemia virus (GaLV) Env or with a chimeric F-MLV Env with a 
GaLV cytoplasmic tail domain (CTD). This incompatibility is modulated by the HIV-1 
accessory protein Vpu. Because the GaLV Env CTD does not resemble tetherin or CD4, 
the well studied targets of Vpu, we sought to characterize the modular sequence in the 
GaLV Env CTD required for this restriction in the presence of Vpu.  Using a systematic 
mutagenesis scan, we determined the motif that makes GaLV Env sensitive to Vpu is 
INxxIxxVKxxVxRxK.  This region in the CTD of GaLV Env is predicted to form a 
helix.  Mutations in the CTD that would break this helix abolish sensitivity to Vpu.  
Although many of these positions can be replaced with amino acids with similar 
biophysical properties without disrupting the Vpu sensitivity, the final lysine residue is 
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required. This Vpu sensitivity sequence appears to be modular, as the unrelated Rous 
sarcoma virus (RSV) Env can be made Vpu sensitive by replacing its CTD with the 
GaLV Env CTD.  In addition, F-MLV Env can be made Vpu sensitive by mutating two 
amino acids in its cytoplasmic tail to make it resemble more closely the Vpu sensitivity 
motif. Surprisingly, the core components of this Vpu sensitivity sequence are also present 
in the host surface protein CD4, which is also targeted by Vpu through its CTD. 
Keywords: Vpu; GaLV; F-MLV; CD4; Vpu sensitivity motif; Envelope protein 
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Introduction: 
Human immunodeficiency virus (HIV-1), like many viruses, is capable of 
assembling infectious viral particles using the surface glycoproteins from foreign viruses 
by a process termed pseudotyping.  However, not all virus/glycoprotein pairs are able to 
complement one another.  HIV-1 is compatible with glycoproteins from many families of 
viruses including rhabdoviruses, other retroviruses, and filoviruses, but the compatibility 
does not strictly follow family lines (135, 156, 214).  For instance, HIV-1 is compatible 
with the glycoprotein from the gammaretrovirus Friend murine leukemia virus (F-MLV 
Env), but it is not compatible with the glycoprotein from gibbon ape leukemia virus 
(GaLV) Env, even though F-MLV and GaLV belong to the same genus (50, 69, 118). 
GaLV is a gammaretrovirus found in captive gibbon apes.  It is closely related to a 
retrovirus found in wild koalas (koala retrovirus, KoRV), but both viruses are believed to 
be fairly recent introductions that likely were derived from endogenous mouse 
retroviruses [reviewed in (275)].  The F-MLV and GaLV Env glycoproteins display 48% 
identity at the amino acid level.  Both proteins have a native molecular weight of ~85 
kDa, and both are cleaved by a cellular protease into the 70 kDa surface (SU) and 15 kDa 
transmembrane (TM) domains, which remain associated after cleavage. Both the F-MLV 
and GaLV TM domains are additionally cleaved in their cytoplasmic tail domain (CTD) 
into a 12 kDa (p12E) and a 2 kDa peptide (p2, or R-peptide) by the virus-encoded 
protease during the viral assembly process (118, 224). This R-peptide cleavage is 
required for the viral glycoproteins to become fusogenically active (224). The component 
of GaLV Env that causes the incompatibility with HIV-1 has been mapped to its CTD 
(50, 269).  Recently, we and others demonstrated that the incompatibility of HIV-1 with 
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glycoproteins containing the CTD from GaLV Env is dictated by the HIV-1 accessory 
protein Vpu (52, 167).  In the presence of Vpu, GaLV Env CTD containing glycoproteins 
are prevented from being incorporated into HIV-1 particles; whereas, deletion of Vpu 
restores incorporation of these glycoproteins and infectivity of the resulting HIV-1 
particles.  The mechanism for this GaLV Env exclusion is not known, although it has 
been suggested that this may be affected by difference in trafficking of Env in the 
presence of Vpu (52). 
 
Vpu is an 81 amino acid HIV-1 protein that contains an N-terminal membrane-
spanning domain followed by an ~50 amino acid cytoplasmic tail (270).  Vpu is unique to 
HIV-1 and a few closely related lentiviruses.  The first and most widely studied function 
of Vpu is to promote the degradation of the host surface protein CD4, the primary 
receptor for HIV-1.   Since HIV-1 Env can bind to CD4 during transit through the 
endoplasmic reticulum (ER), binding can result in the proteins being sequestered in the 
ER.  This can result in severe impairment to viral propagation, and has been thought to be 
a major reason for Vpu’s role in CD4 degradation (154, 239, 274).   The C-terminal 
cytoplasmic domain of Vpu interacts with the CD4 cytoplasmic tail; consequently, the E3 
ubiquitin ligase complex bearing TrCP is recruited to CD4 (179). CD4 is subsequently 
ubiquitinated and degraded by the proteasome (179, 238, 250). TrCP is critical for this 
function, and the phosphoserine residues in positions 52 and 56 of Vpu are required for 
TrCP recruitment and for CD4 degradation (255). 
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Vpu also enhances viral release by modulating the host defense protein tetherin 
(also known as BST-2, CD317 or HM1.24) (271, 281).  Tetherin is an interferon- 
induced anti-viral protein that contains an N-terminal membrane-spanning domain and a 
C-terminal glycophosphatidylinositol anchor that physically tethers enveloped viruses to 
the infected cell’s surface after release. Human tetherin expression at the cell surface is 
efficiently modulated by Vpu, resulting in enhanced virus release (271, 281). Unlike with 
CD4, recognition of tetherin by Vpu appears to be facilitated through the membrane 
spanning domains of the two proteins (81, 220). Vpu with a scrambled membrane 
spanning domain cannot enhance viral release or modulate tetherin activity (217, 253, 
278). Tetherin antagonism by Vpu has been reported to be -TrCP dependent (117, 188) 
and has been reported to involve the sequestration of tetherin in the trans-Golgi network 
or the endo-lysosomal compartments (73).   In addition to modulating tetherin and CD4, 
Vpu has also been reported to degrade or modulate other host cellular proteins, including 
TASK-1, MHC-I, MHC-II, CD1d and NTB-A (107, 109, 135, 191, 259).  
 
GaLV and HIV-1 infect different primates and belong to different genera of 
retroviruses. The reason for the antagonism of GaLV Env by HIV-1 Vpu is not clear. We 
hypothesize that the proteins containing the GaLV Env CTD resemble human proteins 
that are normally targeted by Vpu and are mistakenly recognized by Vpu and excluded 
from viral particles. The possibility that the resemblance between GaLV Env and the 
natural target of Vpu has a functional significance cannot be excluded. An alanine-
scanning mutagenesis strategy combined with a single-round infectivity assay performed 
55 
 
in the presence or absence of Vpu was performed to identify the precise amino acid 
sequence in the GaLV Env CTD that confers Vpu sensitivity. The primary protein 
sequence conferring sensitivity to Vpu was further validated by showing that additional 
viral glycoproteins could be made sensitive to Vpu by mutating select amino acid 
residues to match the identified Vpu-sensitivity sequence.   
 
Materials and Methods 
Plasmids 
The ecotropic F-MLV Env (isolate 57) expression construct was kindly provided 
by Walther Mothes (Yale University). The F-MLV/GaLV chimeric Env construct 
containing the full-length form of GaLV Env CTD was constructed using oligonucleotide 
linkers coding for the cytoplasmic tail of GaLV.  These oligonucleotides were inserted 
between the ClaI site (encoded within DRL amino acid coding sequence, 30 amino acids 
upstream of the C-terminus as shown in Figure 2-1), and the EcoRI site that occurs after 
the stop codon in the cytoplasmic tail region of the F-MLV Env expression construct. 
Plasmids expressing the truncated forms of the F-MLV/GaLV Env (i.e., lacking 4, 8, 9, 
10, 11 or 12 amino acids at the C-terminus) were constructed by introducing a stop codon 
at the appropriate position on the linkers used to replace the fragment between ClaI and 
EcoRI.  Mutant chimeric F-MLV/GaLV Env expressing constructs were made in the 
context of the 8 F-MLV/GaLV chimeric Env (lacking 8 amino acids at the C-terminus) 
and were constructed by site-directed mutagenesis of the fragment between ClaI and 
EcoRI. Two silent mutations were made from ‘ctcatt’ to ‘ctgatc’ to encode LII amino 
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acids 48 residues upstream of the C-terminus in the transmembrane region to introduce a 
BclI site into the region encoding the transmembrane domain of F-MLV Env. For 
mutations in the transmembrane region or the membrane proximal cytoplasmic domain of 
the chimeric F-MLV/GaLV Env, the fragment between BclI and EcoRI was replaced by 
PCR and the respective mutations were introduced through the primers.  Order of the 
amino acid mutations indicated in this study is numbered from the C-terminus inward. 
Rous sarcoma virus Schmidt-Ruppin A (RSV) Env with GaLV CTD was created by a 
two-step PCR with oligonucleotides amplifying the sequences from the RSV Env 
transmembrane domain and ectodomain and the GaLV Env CTD. The fragment of DNA 
between EcoRI (encoding ‘GIP’) and SacII (after the stop codon) on the RSV Env 
expression plasmid was replaced by the PCR product. The RSV/GaLV Env fusion 
sequence was CLPC/ILNR.  The C-terminal 27 amino acids in the vesicular stomatitis 
virus-G protein (VSV-G) were deleted, and the amino acids ‘LRV’ were silently mutated 
to introduce a unique MluI restriction site. The GaLV Env CTD, amplified by PCR, was 
introduced into the VSV-G encoding plasmid between MluI (encoding ‘LRV’) and 
BamHI (after the stop codon) sites to construct a VSV-G/GaLV chimeric Env. The VSV-
G/GaLV Env fusion sequence was IHLCI/LNRLV.  The influenza Hemagglutinin (HA) 
and Neuraminidase (NA) expression constructs pEWSN-HA and pCAGGS-WNA15, 
respectively, were kindly provided by Yoshihiro Kawaoka (University of Wisconsin-
Madison).   Influenza HA with GaLV Env CTD was created by a two-step PCR and 
replacement of the fragment between BstXI (encoding ‘ASSLV’) and XhoI (after the stop 
codon).  The HA/GaLV Env fusion sequence was LGAIS/QFIND.  The sequences of the 
inserted region in all the constructs were confirmed by sequencing. NL4-3 derived HIV-
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CMV-GFP was kindly provided by Vineet KewalRamani (National Cancer Institute-
Frederick). This proviral vector lacks the genes encoding Vif, Vpr, Vpu, Nef and Env and 
has a CMV immediate-early promoter driven GFP in the place of Nef.  The Vpu
+
 HIV-
CMV-GFP was created by replacing the fragment between BamHI and SalI sites in HIV-
CMV-GFP from the equivalent BamHI-SalI fragment encoding Vpu from the plasmid 
R8.2 (316).    
Cell culture 
The 293FT cell line was obtained from Invitrogen. The cell line expressing the 
ecotropic F-MLV Env receptor, 293T mCAT-1, was kindly provided by Walther Mothes. 
The 293T TVA cell line expressing the receptor for Rous sarcoma virus (RSV) Env was 
provided by John Young (Scripps Research Institute) (156). All three cell lines were 
maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% 
fetal bovine serum, 2 mM glutamine, 1 mM sodium pyruvate, 10 mM non-essential 
amino acids, and 0.5 mg/ml G418. In phases of cell culture involving transfection or 
transduction, G418 was not added to the medium.  
Infectivity/Vpu sensitivity assays 
Infectivity assays using HIV-CMV-GFP and its derivative were performed by 
transfection of 293FT cells with 500 ng of the HIV proviral DNA and 500 ng of the Env 
or the mutant Env expression construct using 3 l of FuGENE 6 (Roche) or 3 l of 1 
mg/ml polyethylenimine (PEI) (31) in six well plates. When influenza HA or its 
derivatives were used, 293FT cells were transfected with 500 ng of the provirus, 250 ng 
of the HA expression vector or its derivative, and 250 ng of the NA expression vector. 
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The media were replaced 16 to 24 h post transfection in the case of FuGENE or 4 to 6 h 
post transfection in the case of PEI to remove any residual transfection reagent. 
Supernatant was collected 24 h after the media were exchanged and then frozen at -80
o
C 
for at least 2 h to lyse any cells in the supernatant. The supernatant was thawed in a 37
o
C 
water bath and spun at 2500 g for 10 min to pellet any cells or cell debris. For viruses 
pseudotyped with F-MLV Env or influenza HA, 1 ml of the supernatant was applied to 
fresh 293T mCAT-1 cells.  For the transduction of RSV Env pseudotyped viruses, 1 ml 
of the supernatant was applied to fresh 293T TVA cells. Cells were collected 48 h later, 
fixed with 4% paraformaldehyde, and analyzed by flow cytometry using FACScan or 
Accuri C6 flow cytometer systems. Data were analyzed using FlowJo software (version 
7.5.5, Tree Star). Vpu sensitivity is expressed as a ratio of the percentage of cells infected 
with the HIV-1 from provirus lacking Vpu to the percentage of cells infected with the 
HIV-1 from provirus containing Vpu (Figure 2-1B). Relative infectivity is expressed as a 
ratio of percentage of cells infected with Vpu
-
 HIV-1 pseudotyped with a mutant Env to 
the percentage of infectivity with Vpu
-
 HIV-1 pseudotyped with F-MLV Env in the same 
experiment (Figure 2-1B).  
Western blotting 
Transfections for western blots were performed as described for infectivity 
assays. Viral supernatants were spun at 13,200g for 2 h. The pellets were resuspended in 
2X SDS-PAGE loading buffer and the equivalent of 1ml of viral supernatant was 
analyzed by 10% discontinuous SDS-PAGE. Cells were pelleted and resuspended in 1X 
SDS-PAGE loading buffer and approximately 2% of the total amount of cells was 
analyzed in parallel with the viral supernatants. Proteins were transferred manually onto a 
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0.22 m PVDF membrane. The membranes were blocked with 5% nonfat dry milk and 
probed with goat anti-MLV Env gp70 (kindly provided by Alan Rein, NCI-Frederick) 
diluted 1:10000 and anti-HIV p24 hybridoma medium diluted 1:500 (obtained through 
the AIDS Research and Reference Reagent program, Division of AIDS, NIAID, NIH: 
HIV-1 p24 hybridoma [183-H12-5C]) from Bruce Chesebro (49) and anti- HIV MA 
hybridoma medium diluted 1:5 (obtained through ATCC : HB-8975; MH-SVM33C9) 
(247). Blots were then probed with horse radish peroxidase conjugated anti-goat antibody 
diluted 1:10000 or anti-mouse antibody diluted 1:10000, both from Sigma. Luminata 
Crescendo western HRP substrate from Millipore was used for visualization of the 
membranes on a chemiluminescence image analyzer, LAS3000 from Fujifilm. Blots were 
also probed with IR dye 700DX anti mouse IgG and visualized using Odyssey infrared 
imaging system from LI-COR biosciences. 
 
Results 
F-MLV and GaLV are both gammaretroviruses, and the Env proteins of these 
viruses are closely related. The amino acids sequences of the TM domains of these two 
proteins are 65% identical and both proteins contain a conserved viral protease cleavage 
site that removes the C-terminal R-peptide.  The R-peptide itself is less conserved than 
the rest of Env and differs in length by one amino acid (Figure 2-1A).  In spite of these 
similarities, an F-MLV Env that contains the GaLV Env CTD is incompatible with HIV-
1 proviruses that contain Vpu, while wild type F-MLV Env is compatible. This 
incompatibility typically causes a 50- to a 100-fold reduction in the number of infectious 
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HIV-1 particles produced (167).  Vpu’s action on GaLV Env appears mechanistically 
similar to its action on the host protein CD4. GaLV Env and CD4 contain short CTDs 
that dictate Vpu sensitivity.  The modulation of CD4 and GaLV Env by Vpu is abolished 
by mutation of the serine residues at positions 52 and 56 in Vpu (167, 255), but it is not 
affected by mutations in the membrane-spanning domain of Vpu (167, 296).  However, 
the CTD of GaLV Env is similar to the CTD of F-MLV but very dissimilar from the CTD 
of CD4 (Figure 2-1A), and yet GaLV Env but not F-MLV Env is sensitive to Vpu.  In 
addition, while Vpu has typically been thought to target CD4 for degradation, the action 
on GaLV appears distinct.  Vpu prevents GaLV Env CTD-containing F-MLV Env from 
forming infectious particles with HIV-1 but not with F-MLV (50-51, 167), which 
suggests that the mechanism of restriction is not based simply on protein degradation.  
These data suggest that the recognition sequence and modulation mechanism of GaLV 
Env by Vpu is distinct from that of CD4. 
 
The boundary for Vpu sensitivity lies around the tenth amino acid from the C-
terminus  
To identify the precise sequence required for modulation of GaLV Env by Vpu, 
we first defined the C-terminal boundary that confers Vpu sensitivity.  An F-MLV/GaLV 
Env chimera containing the C-terminal 29 amino acid CTD from GaLV Env was 
engineered to lack its C-terminal 4, 8, or 12 amino acids (denoted 4, 8, and 12) 
(Figure 2-2).  The F-MLV/GaLV chimera was used so that the only differences between 
the Vpu-insensitive F-MLV Env and the Vpu-sensitive F-MLV/GaLV Env were in the 
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CTD.  Infectivity experiments were performed in parallel with Vpu
+
 and Vpu
-
 HIV 
proviruses using a 1:1 (wt:wt) ratio of proviral DNA to Env.  This ratio of transfection 
yielded high infectivity and at least a 10-fold reduction in infectivity in the presence of 
Vpu with Env proteins that contained the GaLV CTD.  A Vpu insensitive Env, F-MLV 
Env, was used as a control to ensure that observed differences were due to Vpu.  In all 
cases, infectivity with F-MLV Env was essentially identical with the Vpu
+
 and Vpu
-
 
proviruses.  The F-MLV/GaLV Env 4 and 8 proteins alone remained sensitive to Vpu; 
however, this sensitivity was abolished with the 12 truncation.  Curiously, F-
MLV/GaLV Env chimeras missing 8 to 12 amino acids at the C-terminus produced 
several fold more infectious particles than full-length F-MLV/GaLV Env (Figure 2-2B). 
Full length F-MLV/GaLV Env was incorporated into viral particles less efficiently than 
wildtype F-MLV Env, F-MLV/GaLV Env 8, or F-MLV/GaLV Env 12 (Figure 2-
S1A).  Reduced incorporation of full length GaLV Env into HIV particles, even in the 
absence of Vpu, has been noted previously (51).  The reduction in incorporation also 
correlated with loss in infectivity with these mutant Envs, but did not affect Vpu 
sensitivity (Figure 2-2B, S1b). To further define the Vpu sensitivity boundary, F-
MLV/GaLV chimeric Env proteins lacking 9, 10, or 11 amino acids from the C-terminus 
were created. The sensitivity toward Vpu was reduced stepwise with 9 or 10 amino acids 
being removed. Upon removal of 11 amino acids, the sensitivity toward Vpu was 
abolished (Figure 2-2A, B). Hence the boundary of the region sensitive to Vpu is the 
cytoplasmic tail extending to the Tyr at the tenth position from the C-terminus.  
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Vpu sensitivity motif  
To identify the amino acids required for sensitivity toward Vpu, an alanine 
scanning mutagenesis was performed, starting from the minimal sensitive protein, F-
MLV/GaLV Env 8.  Initially, five amino acids at a time were mutated to alanine in the 
CTD of the chimeric Env. F-MLV/GaLV Env 8 containing mutations (from the C-
terminus) 9-13A, 14-18A, and 24-28A formed infectious particles but were resistant to 
Vpu (Figure 2-S2). The construct with mutations 19-23A, however, did not form 
infectious particles in the presence or absence of Vpu.  We fine tuned the mutagenesis by 
mutating only two amino acids at a time to alanine and observed that 11-12A, 13-14A, 
15-16A, 17-18A, 19-20A, 21-22A, and 25-26A formed infectious particles but were not 
sensitive to Vpu.  The exceptions were 23-24A and 27-28A, which did not produce 
infectious particles in the presence or absence of Vpu, and 9-10A, which produced 
infectious particles and remained sensitive to Vpu (Figure 2-S3).  
 
Finally, the amino acids in the CTD of F-MLV/GaLV Env 8 were mutated 
individually.  Of the 30 amino acids mutated, eight independently abolished sensitivity to 
Vpu.  Mutants were scored as ‘Vpu insensitive’ if the presence of Vpu reduced the 
infectivity by less than four fold.  The Vpu-sensitivity conveying residues were spread 
over a 16-residue segment beginning 26 amino acids from the C-terminus and conveyed 
Vpu sensitivity through the motif INxxIxxVKxLxxRxK (Figure 2-3).  Mutation of amino 
acids V29, R31, N32, and L33 to alanine abolished the production of infectious particles 
with HIV-1 in the presence and absence of Vpu and therefore cannot be excluded as 
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being required for Vpu sensitivity. Several other point mutations altered the infectivity of 
particles produced, but there was no obvious correlation between changes that affect Vpu 
sensitivity and changes that affect infectivity (Figure 2-3).  The ‘sensitivity-motif’ is 
composed largely of hydrophobic amino acids and a few positive charges but is devoid of 
proline and glycine residues, which is consistent with an alpha helical structure.   
 
Modularity of the Vpu sensitivity motif-containing GaLV CTD 
The GaLV Env CTD is required, but not necessarily sufficient, to confer Vpu 
sensitivity. Additional requirements for Vpu sensitivity may be present in F-MLV and 
GaLV Envs.  To determine if this sensitivity is necessary and sufficient for mediating 
Vpu sensitivity, the CTD of RSV Env, HA, and VSV-G were replaced with the Vpu 
sensitivity motif from GaLV Env. Replacement of the CTDs of VSV-G and HA resulted 
in chimeric proteins unable to form infectious particles with HIV-1 in the presence or 
absence of Vpu (data not shown). However, replacement of the RSV CTD with the Vpu 
sensitivity motif from GaLV resulted in a chimera that produced infectious particles with 
HIV-1 and was sensitive to Vpu (Figure 2-4). Wildtype RSV Env could pseudotype HIV-
1 particles efficiently and remained Vpu insensitive. Hence, sensitivity toward Vpu can 
be conferred on other proteins by exchanging the CTD with the GaLV Env CTD, but 
determination of whether the protein can form infectious particles depends on additional 
factors. 
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Sensitivity toward Vpu requires a putative alpha helix-  
The frequency and positioning of hydrophobic amino acids in the GaLV Env 
CTD is consistent with an alpha helical domain.  Secondary structure predictors indicate 
that the CTDs of F-MLV Env and GaLV Env are alpha helical with an unstructured chain 
of nine amino acids at the C-terminus (35, 130, 276). The putative alpha helix was 
disrupted to determine if this structure is important for Vpu sensitivity. Glycine and 
proline have a low propensity to fall into an alpha helix (212).  Several point mutations 
were made throughout the Vpu-sensitivity sequence by changing individual amino acid 
residues to proline.  Mutations of six different amino acids to proline in a stretch of 16 
amino acids each abolished sensitivity toward Vpu (Figure 2-5B). In each case, HIV-1 
particles pseudotyped with these mutant Envs displayed viral infectivity equivalent to the 
parent protein, suggesting the mutations did not alter normal protein function. These data 
are consistent with an alpha helix in the CTD of GaLV Env being required for Vpu 
sensitivity but not for regular infectivity function of Env in cell culture. 
 
If the GaLV Env CTD is represented as an alpha helix, then all amino acids in the 
sensitivity motif, with the exception of R13, align on one side of the helix. Positions a 
and d in the helix contain largely hydrophobic amino acids and hence may be the 
interaction face of a coiled coil structure (Figure 2-5B). In fact, F-MLV Env is known to 
possess a trimeric structure in the ectodomain, and it is conceivable that the cytoplasmic 
domain also trimerizes with these hydrophobic amino acids providing the interaction for 
trimerization (276). The protease cleavage site for R-peptide removal is located at 
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position g of the helix and is free from the interaction face to be accessed by the viral 
protease to cleave the R-peptide and activate the Env (276). At position e of the helix is a 
positively charged face in the predicted alpha helix.     
 
F-MLV Env can be made sensitive to Vpu 
To validate the Vpu sensitivity motif, we tested whether Vpu sensitivity could be 
conferred to F-MLV Env with minimal changes. Although the F-MLV Env and GaLV 
Env CTDs differ at 12 residues out of 29 positions, only four of these positions are part of 
the predicted Vpu sensitivity motif (Figure 2-6A).  Of these four, we focused on K11, 
K18, and N25, which are in the position e of the putative alpha helix (Figure 2-6B). The 
tail lengths of F-MLV and GaLV Env differ by one amino acid. N25, K18, and K11 in 
the GaLV Env from the C-terminus correspond to K26, Q19, and Q12 in the F-MLV Env 
from the C-terminus. These amino acids fall on the same face of the putative alpha helix.  
Q12K mutation alone conferred a slight sensitivity to Vpu upon F-MLV Env.  However, 
mutations Q12K and Q19K were sufficient to make F-MLV Env acutely sensitive to 
Vpu.   Q12K and K26N mutations, in contrast, were not sufficient to confer Vpu 
sensitivity (Figure 2-6C).   
 
Vpu sensitivity requires lysine at the eleventh position from the C-terminus 
Vpu modulation of the cellular targets CD4 and tetherin have both been proposed 
to involve ubiquitination.  Ubiquitin, a 76 amino acid and 19 kDa moiety, may be 
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conjugated to proteins to modulate various functions, such as altered trafficking or to 
target proteins for proteasomal mediated degradation. Ubiquitin is most often conjugated 
to lysine residues in the target protein. The CTD of the F-MLV/GaLV chimeric Env 
contains two lysine residues, both of which are part of the Vpu sensitivity motif (Figure 
2-3). In the light of the ability to make F-MLV Env sensitive to Vpu, each of the lysines 
was tested for necessity towards Vpu sensitivity. Each of the lysines was mutated to 
arginine, which is biophysically similar to lysine but not prone to ubiquitination. When 
both lysines were mutated to arginine, Vpu sensitivity was abolished (Figure 2-6D). 
Individually, the K18R was slightly less sensitive to Vpu, but the K11R abolished Vpu 
sensitivity. Hence, the lysine at the eleventh position from the C-terminus is required for 
Vpu sensitivity. When K18 was mutated to Q, to better resemble the F-MLV protease 
cleavage site (6), sensitivity was abolished (Figure 2-3). These data suggest that a 
positively charged amino acid is required at the eighteenth position for sensitivity toward 
Vpu and a lysine is specifically required at the eleventh position. Collectively, these data 
suggest that the Vpu sensitivity motif consists of a C-terminal alpha helix with a 
hydrophobic face adjacent to a positively charged face, including at least one lysine. 
 
Loss of the processed form of a Vpu-sensitive Env in the presence of Vpu 
Our lab has previously reported that Vpu specifically blocks the incorporation of 
the F-MLV/GaLV Env into HIV-1 particles (167). It has been reported previously that 
Vpu expression results in a loss of cleaved TM protein in cells (51). To ensure that the 
addition of Vpu does not enforce reduction in infectivity by means other than preventing 
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incorporation of Env into HIV-1 particles, cells were transfected with 500 ng of HIV-
CMV-GFP with or without Vpu and 500 ng of different Env constructs as indicated in 
Figure 2-7A. Env is produced as a gp85 precursor and then processed by a cellular 
protease into gp70 (SU) and p15 (TM). In the case of the Vpu sensitive Envs, in the 
presence of Vpu, the processed or the gp70 form of the Env is lost and this correlates 
with the loss of Env incorporation into viral particles (Figure 2-7A). The infectivity of the 
pseudotyped viral particles in these experiments was also determined and Vpu sensitivity 
was calculated (Figure 2-7B).  
 
To revisit the question of whether GaLV Env and CD4 contain the same Vpu 
target, we re-examined the sequence similarity in light of the identification of the precise 
Vpu sensitivity motif between the GaLV Env CTD, other gamma retroviral Env CTDs 
and the human CD4 CTD (Figure 2-8).  Among the gammaretroviruses very closely 
related to GaLV, namely, KoRV and Wooly Monkey Sarcoma virus (WMSV), the amino 
acids contributing to Vpu sensitivity are conserved.  The KoRV Env contains a K18R 
variation, but this CTD would be predicted to remain Vpu sensitive (Figure 2-6).  All 
gammaretroviral Env CTDs maintained the predicted hydrophobic alpha helix, but no 
other Envs contained lysines at the critical 11
th
 and 18
th
 positions.  In fact, the vast 
majority of gammaretroviral Envs contain highly conserved glutamines residues at these 
two positions.  In contrast, the human CD4 CTD is predicted to contain an alpha helix 
with hydrophobic residues at the appropriate locations, and contains lysines in the 
positions equivalent to the 11
th
 and 18
th
 positions (Figure 2-8).  Collectively, these data 
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suggest that GaLV Env and CD4 unexpectedly contain sequences with equivalent Vpu 
recognition sequences. 
 
Discussion 
In this study, the sequence in GaLV Env CTD that modulates Vpu sensitivity has 
been identified comprehensively to be INxxIxxVKxxVxRxK. Previous reports had 
identified the KRLLSEKKT sequence in CD4 to be the minimal sequence required for 
restriction by Vpu and was later narrowed down to EKKT in the CD4 CTD (153, 285, 
308). This study, however, shows that the lysines, separated by 7 amino acids or two 
turns of the helix, within the KRLLSEKKT are required. The predicted motif required for 
restriction is essentially an alpha helix with a positively charged face that includes at least 
one lysine and a hydrophobic face. The alpha helix structural requirement in the CD4 
CTD for Vpu-mediated downregulation has been previously reported (308).  
 
Vpu is thought to modulate CD4 expression by inducing its polyubiquitination 
and subsequent degradation from the ER (298-299). The enhanced turnover and 
ubiquitination of CD4 in the presence of Vpu in the CD4 CTD is well documented (179, 
250). Ubiquitination of proteins occurs predominantly at lysine residues. However 
mutational studies on the CD4 CTD have indicated a role for amino acids other than 
lysine in Vpu-mediated degradation (21, 174). Vpu-dependent CD4 ubiquitination is 
abolished only when lysine, serine, and threonine in the CD4 CTD are mutated (174). In 
our study to identify amino acids involved in Vpu-dependent modulation of GaLV Env, 
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we found that serines in the GaLV Env CTD are not necessary. The only amino acids 
likely to be ubiquitinated in the motif are the two lysine residues (Figures 3, 6 and 8). In 
fact, F-MLV Env could be made sensitive to Vpu by introduction of these two lysines in 
the appropriate locations of the F-MLV Env CTD (Figure 2-6).  
 
Our finding that the membrane proximal lysine (K18) can be replaced by 
arginine, but not glutamine, without affecting Vpu sensitivity (Figure 2-5) appears to 
differ from the findings of a previous report (7).  Christodoulopoulos et al. reported that 
mutating this lysine residue (denoted K618 in the previous report) to arginine abolished 
Vpu sensitivity and to glutamine partially alleviated sensitivity.  The reason for this 
discrepancy is not known, but two key differences between this study and the previous 
study are notable.  First, the present study analyzed the GaLV Env CTD in the context of 
an F-MLV Env protein; the previous study was performed with a full-length GaLV Env.  
Second, the output of the current study was loss of infectious particle production; the 
output of the previous study was loss of mature GaLV Env expression within the cell.  In 
the present study the K18R mutation did reduce sensitivity to Vpu, but it did not abolish 
it.  Thus, the difference between these results and previous results could simply reflect 
differences in sensitivity of the two assays. 
 
In addition to identifying the motif, this current study found that when the 
sequences of GaLV Env CTD and CD4 CTD are aligned in the context of the Vpu 
sensitivity motif, the CD4 CTD also contains a sequence consistent with the GaLV Env 
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sensitivity motif, namely two lysines separated by two helicals of a predicted alpha helix 
(Figure 2-8). TASK-1, another protein reported to be targeted by Vpu (107), also contains 
a sequence consistent with this sensitivity motif. Tetherin is reported to be targeted by 
Vpu through its transmembrane region rather than its CTD; not surprising, no sequence 
consistent with the GaLV Env Vpu sensitivity motif is found in tetherin’s cytoplasmic 
domain. It is likely that Vpu-based restriction of proteins by cytoplasmic tail recognition 
is different from transmembrane domain recognition (250)(37).  
 
The infectivity of the F-MLV/GaLV 8 Env is greater than that of the full-length 
F-MLV/GaLV Env. These observations indicate the presence of an inhibitory/ regulatory 
sequence in the C-terminal eight amino acids in the GaLV Env CTD.  Because these 
amino acids are all removed by R-peptide cleavage, their inhibitory effect presumably 
occurs prior to cleavage. Indeed, F-MLV/GaLV Env is not incorporated into HIV-1 
particles at the same levels as wildtype F-MLV Env (Figure 2-S1).  A similar 
phenomenon has been observed with the gammaretrovirus Env protein from the feline 
endogenous retrovirus RD114.  This Env is poorly incorporated into lentiviral particles 
and the inhibitory sequence has been mapped to an acidic motif in the last six amino 
acids of the protein (27).  The loss of incorporation is attributed to alterations in protein 
trafficking due to the acid motif.  Altering two of the negatively charged amino acids 
alleviated the retroviral restriction (27).  Although the C-terminal tail of GaLV Env is not 
as negatively charged as RD114 Env, the last eight amino acids of GaLV Env do include 
two negatively charged residues.  
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Gammaretroviral Env proteins have been important components of several gene 
therapy applications.  Because different applications required combining different 
virus/glycoprotein combinations, it is important to understanding the molecular details 
that lead to compatibility among these combinations.  This study provides an 
understanding of what causes incompatibility between a gammaretroviral Env and a Vpu 
containing lentivirus. We can now predict other glycoproteins that are likely to be 
incompatible with such a virus and also the information provided here could be used to 
eliminate this incompatibility. 
 
In conclusion, the Vpu sensitivity motif appears to be an alpha helix on the 
cytoplasmic side of a membrane protein with a positively charged face including at least 
one lysine and a hydrophobic face.  This information can potentially be used to identify 
additional Vpu target proteins by in silico screening for proteins with these properties and 
to develop newer lentivirus based gene transfer vectors.  
 
Acknowledgements 
We thank Dr. Vineet KewalRamani, Dr. John Young, Dr. Yoshihiro Kawaoka, 
Dr. Alan Rein and Dr. Walther Mothes for reagents. The following reagent was obtained 
through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, 
NIAID, NIH: HIV-1 p24 Hybridoma (183-H12-5C) from Dr. Bruce Chesebro. Also we 
thank Terri Lyddon, Devon Gregory and Brandon Jordan for timely help, discussions and 
support during the course of this study. 
72 
 
Financial aid for this study was obtained from NIH, NIAID , in the form of a grant to 
MCJ (R21 AI087448-01A1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
73 
 
FIGURE 2-1. Env Representation and Experimental Methodology 
(a)  Schematic of the MLV and GaLV Env proteins. The amino acid sequences in the 
CTD of F-MLV Env, GaLV Env and CD4 are depicted. The arrow indicates the point at 
which the MLV Env CTD was exchanged for the equivalent sequence from GaLV Env 
CTD in the F-MLV/GaLV chimeric Env construct. The vertical lines indicate the 
alignment of the amino acid residues between the CTD of F-MLV Env and GaLV Env or 
between GaLV Env and CD4. (b) Schematic of the single round infectivity assay. HIV-
CMV-GFP (+/- Vpu) is cotransfected with different Env constructs into 293 FT cells.  
Supernatant is applied to fresh 293T mCAT-1 cells and infected cells are quantitiated by 
flow cytometry. Projected on the plot is the side scatter (Y-axis) against the GFP 
fluorescence (X-axis). Vpu sensitivity is quantified as a ratio of infectivity (percent cells 
infected) from provirus without Vpu divided by the infectivity from a parallel assay using 
a provirus containing Vpu. Relative infectivity is quantified as a ratio of infectivity in the 
absence of Vpu to infectivity with WT F-MLV Env in the same experiment 
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Figure 2-1: Env Representation and Experimental Methodology 
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Figure 2-2.  HIV-1 Vpu modulates infectivity with F-MLV/GaLV Env 
 (a)  Infectivity plots are as described in Figure 1 and the percentage of infected 
cells is indicated in the dot plots. (b) Scheme of truncated mutants. ‘X’ represents a 
deleted amino acid and ‘~’ represents an unchanged amino acid. Vpu sensitivity and 
relative infectivity has been calculated as in Figure 1 and is the average of two 
experiments. Mean relative infectivity and SD in the experiments is shown. 
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Figure 2-2:  HIV-1 Vpu modulates infectivity with F-MLV/GaLV Env 
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Figure 2-3.  Scanning mutagenesis of the GaLV CTD 
 Mutants are depicted as in Figure 2. A letter at a particular position represents 
mutation of the amino acid in that position. Vpu sensitivity relative infectivity has been 
calculated as shown in Figure 1 and is the average of two experiments for mutations in 
amino acid residues 32 through 35; the average of three experiments for mutations of 
amino acids 11, 12, 13, 15, 16, 23, 27, 30, 36, 37 and 38; and the average of four 
experiments for mutations of residues 18, 19, 20, 22 and 26; the average of five 
experiments for mutations of residues 10, 17, 21, 24, 25, 28, 29, 31 and 39; and the 
average of seven experiments for mutation of amino acid residue 14; average of 31 
experiments for 8 construct; NA, not applicable. Mean relative infectivity and the SD in 
the experiments is shown.  
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Figure 2-3:  Scanning mutagenesis of the GaLV CTD 
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Figure 2-4. RSV/GaLV Env is Vpu sensitive 
 CTD Amino acid sequences of the indicated Envs are depicted. Vpu sensitivity 
with F-MLV Env, 8 and 12 Envs are the average of 4 experiments, the average of  3 
experiments for RSV/GaLV Env and the average of 2 experiments for RSV Env. Mean 
relative Infectivity +/- SD in the experiments is shown . 
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Figure 2-4: RSV/GaLV Env is Vpu sensitive 
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Figure 2-5. Vpu sensitivity requires a predicted alpha helix 
 (a) Amino acid sequences are indicated as in Figure 2. Vpu sensitivity and 
relative infectivity is calculated as shown in Figure 1 and is the average of three 
experiments for mutations of residues 11, 14 and 17; the average of five experiments for 
mutation of residue 23 and the average of eight experiments for mutation of residues 20 
and 26; the average of 11 experiments for F-MLV and 8 Envs. Mean relative infectivity 
with SD in the experiments is shown. (b) Helix representation of GaLV Env CTD is 
depicted starting from L33 at position d and ending at Y10 at position f. Amino acids 
required for Vpu sensitivity are underlined. 
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Figure 2-5: Vpu sensitivity requires a predicted alpha helix 
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Figure 2-6. F-MLV Env can be made sensitive to Vpu 
 (a) F-MLV and GaLV Env CTD along with the Vpu sensitivity motif are aligned 
and the differences between F-MLV and GaLV Env CTD within the motif are boxed. (b) 
The alpha helical representation is of the F-MLV Env CTD starting from L34 at position 
d and ending at Y11 at position f. F-MLV Env CTD differs from GaLV Env CTD within 
the Vpu sensitivity motif at the underlined positions (c) F-MLV Env CTD has been 
mutated to more closely resemble the Vpu sensitivity motif. Amino acid sequences are 
indicated as in Figure 2-2. Vpu sensitivity and relative infectivity are calculated as shown 
in Figure 2-1 and is the average of 6 experiments for F-MLV Env mutants and the 
average of 9 experiments for the WT F-MLV Env. (d) The lysines that can render F-
MLV Env sensitive to Vpu have been mutated in the GaLV Env CTD. Data for K18Q 
Env from Figure 2-3 has been included for comparison. Vpu sensitivity shown is the 
average of 4 experiments for the 8 and F-MLV/GaLV K11R, K18R Envs; the average 
of 3 experiments for K11R and K18R single mutation Envs.  Mean  relative infectivity 
and SD in the experiments are shown. 
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Figure 2-6: F-MLV Env can be made sensitive to Vpu 
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Figure 2-7. Loss of the processed form of a Vpu sensitive Env in the presence of Vpu 
 (a) 293 FT cells were transfected with HIV-CMV-GFP +/- Vpu and different 
Envs as indicated. Western blot analysis was performed on the transfected cells and 
pelleted viral supernatants. Representative image of the experiments performed has been 
shown. (b) Vpu sensitivity of the various envelopes used in these experiments is shown 
and is an average of 19 independent experiments. Error bars represent standard deviations 
from the mean from 19 independent experiments. 
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Figure 2-7: Loss of the processed form of a Vpu sensitive Env in the presence of Vpu 
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Figure 2-8. CTD sequences of Gammaretroviruses 
Alignment the CTDs from GaLV Env, WMSV Env, KORV Env, Moloney 
murine leukemia virus (MoMLV) Env, F-MLV Env, Feline leukemia virus (FLV) Env, 
Kirsten murine leukemia virus (KMVL Env), xenotropic murine leukemia related virus 
(XMRV), endogenous retroviruses (RV) and human CD4 CTD along with the Vpu 
sensitivity motif.   Dark boxes highlight the critical lysine positions, light boxes highlight 
the other residues critical for Vpu sensitivity in GaLV Env.  
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Figure 2-8: CTD sequences of Gammaretroviruses 
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Figure 2-S1. Incorporation of Env into viral particles 
(a) A representative Western blot showing Env and HIV-1 Gag expression in 
transfected cells and in viral pellets. (b) Bar graph shows the infectivity or pseudotyped 
HIV virions with each of the Envelopes indicated.  Infectivity shown here is the average 
of 4 experiments and the whiskers represent the standard deviation. 
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Figure 2-S1: Incorporation of Env into viral particles 
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Figure 2-S2. Alanine scanning mutagenesis 
Amino acid sequences are depicted as in Figure 2-2. Vpu sensitivity has been 
calculated as in Figure 2-1 and is the average of two experiments for the 5 alanine 
mutants and the average of three experiments for the F-MLV and 8 mutants. Mean 
relative infectivity and SD in the experiments are shown.  
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Figure 2-S2: Alanine scanning mutagenesis  
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Figure 2-S3. Alanine scanning mutagenesis 
Amino acid sequences are depicted as in Figure 2-2. Vpu sensitivity has been 
calculated as in Figure 2-1 and is the average of 3 experiments for the mutants 19A-20V, 
21-22A, 25-26A, 27-28A, the average of 4 experiments for 9-10A, 11-12A, 15-16A, 23-
24A, the average of 5 experiments for 13-14A, the average of 6 experiments for 17-18A 
and the average of 8 experiments for the F-MLV and D8 mutants. Mean Relative  
percentage Infectivity +/- SD of HIV-1 pseudotyped with the mutant Envs in the absence 
of Vpu is shown  
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Figure 2-S3: Alanine scanning mutagenesis 
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III. Functional complementation of a model target to study Vpu 
sensitivity 
 
Sanath Kumar Janaka, Jared Faurot and Marc C Johnson 
 
This study has been submitted to PLoS One and is under review (113) 
Abstract 
The cytoplasmic tail domain (CTD) of Gibbon Ape Leukemia virus (GaLV) Envelope 
(Env) is modulated by the HIV-1 accessory protein Vpu.  Using Env functional 
complementation, we sought to determine if Vpu sensitivity requires that all of the CTDs 
in the Env trimer be from GaLV Env.  In some cases, the mixed trimers with Vpu 
sensitive and insensitive CTDs remained Vpu sensitive.  However, deletion of the CTD 
from any of the three subunits abolished Vpu sensitivity.   
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Unlike most gammaretrovirus Env proteins, GaLV Env cannot pseudotype HIV-1 
particles (50, 269).  This incompatibility was found to be dictated by the CTD of GaLV 
Env (51, 115, 167).  Recently, we and others have reported that this incompatibility is 
primarily caused by the HIV-1 accessory protein Vpu, which prevents Env proteins with 
the GaLV Env CTD from being incorporated into viral particles (51, 115, 167). The 
CTDs of gammaretroviral Env proteins are predicted to be alpha helical and likely form 
coiled-coil trimers (78, 165, 276). An alanine scanning mutagenetic analysis of the GaLV 
Env CTD helped identify the sequence conferring Vpu sensitivity on GaLV Env CTD to 
be INxxIxxVKxxVxRxK (115). The motif contains two lysine residues that are also 
found in the corresponding positions of the CD4 CTD, another target of Vpu (115). We 
observed that mutation of the hydrophobic residues believed to form the interface of the 
CTD coiled-coil alleviated Vpu sensitivity.  We therefore wanted to understand if this 
putative coiled-coil is required for the Env trimer to be Vpu sensitive, and whether all 
three helices in this trimer must contain the sensitivity motif. To answer these questions, 
we chose to take advantage of functional complementation of receptor-binding defective 
or fusion defective MLV Envs with the CTDs containing a Vpu-sensitive or a Vpu-
resistant helix (313). 
 
The Friend murine leukemia virus (F-MLV) Env protein is a trimer (82), and the 
individual monomers are made up of a 70 kDa surface subunit (SU) and a 15 kDa 
transmembrane unit (TM)(18, 20). SU provides the receptor binding function (15-16, 98, 
172, 209) and TM provides the fusion function (43, 120, 314). Mutations conferring 
receptor binding defects and fusion defects have been identified, and some pairs of 
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defects on two separate Env molecules can functionally complement each other (313-
314). Functionally defective Env constructs lacking receptor binding function or fusion 
function were created, as described previously (313). The D84K mutation, conferring 
receptor binding defect (BD) on the Env and the L493V mutation, conferring a fusion 
defect (FD) on the Env are able to functionally complement one another (313). Env 
constructs with these mutations were generated in the context F-MLV with a GaLV Env 
8 CTD (Vpu sensitive helix) or an F-MLV Env CTD (Vpu resistant helix) (Figure 3-1). 
GaLV Env 8 CTD lacks the C-terminal eight amino acids from GaLV Env and was 
used because the last eight amino acids of GaLV Env reduces infectivity with HIV-1 
cores irrespective of Vpu (115).  Also, BD and FD Envs with most of the CTD deleted 
(25) were generated.  
 
Gammaretroviral Envs with different CTDs complement each other 
Infectivity assays with HIV-CMV-GFP were performed with pairs of BD and FD 
Env constructs to confirm that the proteins are able to complement each other as 
previously described (313). The individual BD and FD Envs do not produce infectious 
particles on their own (Figure 3-2A) but each BD construct was able to complement each 
FD Env with variable efficiency (Figure 3-2B).  Infectivity with wildtype (WT) F-MLV 
Env in each experiment was used to normalize the data and obtain complementation 
efficiency. While highly related Envs have been known to form mixed trimers (41), 
infectivity data from this assay shows that Envs with different CTDs can still 
complement each other functionally.  
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Mixed Env trimers can be Vpu sensitive 
To understand the Vpu sensitivity of the different Env trimers, pairwise 
transfections with complementation pairs were performed in the presence or absence of 
Vpu as previously described ((115), Figure 3-2B).  Vpu sensitivity was calculated as the 
ratio of infectivity in the absence of Vpu to the infectivity in the presence of Vpu (Figure 
3-3).  As expected, the Env trimers that contained only F-MLV CTDs was Vpu resistant 
and the Env trimers that contained only GaLV 8 CTDs was Vpu sensitive (Figure 3-2B, 
3). With mixed trimers, infectivity of the complementation pair of a BD F-MLV/GaLV 
8 (Vpu sensitive) with a FD F-MLV Env (Vpu resistant) was 20-fold higher in the 
absence of Vpu (Figure 3-2B, 3), suggesting that Vpu sensitivity does not require all 
three CTDs to contain the sensitivity sequence. However, infectivity of the reciprocal 
complementation pair, with a FD F-MLV/GaLV 8 Env and a BD F-MLV Env, was only 
1.5 fold higher in the absence of Vpu (Figure 3-2B, 3).  This suggests that the SU domain 
of Env may be able to partially complement independent of its Vpu-sensitive TM subunit. 
Modularity of the receptor binding function has been previously reported (13). 
 
Vpu sensitivity is conferred on a functionally complemented Env complex only if all 
the three CTDs are present 
The hydrophobic amino acids in the ‘vpu-sensitivity sequence’ may form a 
coiled-coil interface in the predicted alpha helix (276), and so we tested whether F-
MLV/GaLV Env proteins with fewer than three CTDs could remain Vpu sensitive.  For 
this, we complemented F-MLV Env 25 with F-MLV and F-MLV/GaLV8 Env.  F-
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MLV 25 remains functional and Vpu resistant (115, 167). Despite the lack of CTD, 
functional complementation occurred with each of these pairs, but the pairs were all Vpu 
resistant (Figure 3-2B and 3).  Loving et al. (165) have shown with electron 
cryotomography reconstructions that the TM of a full length Env is in the form of a 
closely packed density perpendicular to the membrane prior to R-peptide cleavage.  They 
suggest that TM is held in this closely packed form by CTD-CTD interactions that are 
relieved by R-peptide cleavage. Together, these pieces of data support a model wherein 
the gammaretroviral Env CTD forms a trimeric helix bundle and that Vpu sensitivity can 
only be conferred in the context of this structure.  
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Figure 3-1 Schematic of the gammaretroviral Env proteins 
The amino acid sequences in the CTD of F-MLV Env and GaLV Env are 
depicted. Truncations in the CTD of the Envs, F-MLV 25 and F-MLV/GaLV 8 are 
indicated. The cartoon has been adapted from Figure 1 of (115). 
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Figure 3-1: Schematic of the gammaretroviral Env proteins 
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Figure 3-2 Defective Env pairs with different CTDs complement each other 
functionally 
 (A) Infectivity of the indicated Envs relative to infectivity with F-MLV Env. 
Data shown is the average of two experiment s. (B)Infectivity of complementation pairs 
in the presence or absence of Vpu, relative to infectivity with F-MLV Env. Data shown is 
the average of three experiments and the error bars indicate SD in the experiments. 
Welch’s T- test was performed to determine p- values, indicative of statistical 
significance. NS- Non significant; BD- Binding defective; FD- Fusion defective.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
103 
 
Figure 3-2: Defective Env pairs with different CTDs complement each other 
functionally 
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Figure 3-3: Mixed Env trimers can be Vpu sensitive 
Sensitivity to Vpu of each complementation pair is indicated. The degree of Vpu 
sensitivity is indicated within parantheses as a ratio of infectivity in the absence of Vpu to 
infectivity in the presence of Vpu. Data shown is the average of three independent 
experiments in Figure 3-2B.Vpu
R
- Vpu resistant; Vpu 
S
- Vpu sensitive.  
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Figure 3-3: Mixed Env trimers can be Vpu sensitive 
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Abstract 
During human immunodeficiency virus 1 (HIV-1) assembly the host proteins 
CD4, the HIV-1 receptor, and tetherin, an interferon stimulated anti-viral protein, reduce 
viral fitness.  To counteract these host proteins, the HIV-1 accessory gene Vpu is thought 
to target both CD4 and tetherin through two distinct mechanisms. Modulation of CD4  
likely  occurs through proteasomal degradation from the endoplasmic reticulum.  The 
exact mechanism of tetherin modulation is less clear, with possible roles for degradation 
and alteration of protein transport from and to the plasma membrane.  Investigation of 
Vpu function historically relied on different assays for CD4 and tetherin, many of which 
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require exogenously expressed Vpu, potentially leading to variability in expression.  
Thus, few studies have investigated these two Vpu functions in parallel assays, making it 
difficult to draw direct comparisons between Vpu targeting of tetherin and CD4. 
Here, we present a rapid assay to simultaneously investigate Vpu-targeting of 
both tetherin and a CD4-like stand-in, gibbon ape leukemia virus envelope (GaLV Env) 
with a comprehensive mutagenic scan of Vpu in its native proviral context to identify 
features required for activity.  We previously reported that Vpu modulates the envelope 
protein from GaLV and prevents its incorporation into HIV-1 particles, presumably in a 
CD4-like manner through recognition of a shared sensitivity motif in the cytoplasmic 
tails of CD4 and GaLV Env.  Interestingly, we observed considerable overlap in the Vpu 
sequences required to modulate tetherin and GaLV Env.  We found that features in the 
cytoplasmic tail of Vpu, specifically within the cytoplasmic tail hinge region, were 
required for modulation of both tetherin and GaLV Env.  We observed a role for 
previously reported critical transmembrane amino acids in the restriction of tetherin but 
not GaLV Env.  We propose that Vpu may target both proteins in a mechanistically 
similar manner, albeit in different cellular locations.   
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Introduction 
Vpu is an 81-86 amino acid, type-1 transmembrane protein found in HIV-1 and a 
few closely related strains of SIV.  Vpu modulates a wide range of targets including the 
host proteins CD4, tetherin, IkB, MHC-II, NTB-A, and the gammaretroviral gibbon ape 
leukemia virus (GaLV) envelope (Env) (28-29, 52, 110, 116, 169, 199, 259, 300).  Of 
these functions, Vpu’s abilities to degrade cellular CD4 and tetherin (BST-2, CD137) 
have been the best described (30, 92, 203, 243).  CD4 is the primary receptor for HIV-1.  
Vpu targets newly synthesized CD4 in the rough endoplasmic reticulum (RER) through 
interactions between the cytoplasmic tails (CT) of Vpu and CD4, recruiting the Skp1-
Cullin-β-TrCP E3-ubiquitin ligase complex, resulting in the subsequent proteasomal 
degradation of CD4 (29, 48, 85, 175, 178, 251, 297).  The cytoplasmic tail (CT) of Vpu is 
unambiguously required for CD4 modulation, but it is disputed whether the membrane 
spanning domain (MSD) also plays a specific role (103, 173, 244, 252, 279). 
 
Tetherin is an interferon inducible, type-II transmembrane anti-viral protein with 
a C-terminal GPI-anchor.  Tetherin, as its name suggests, “tethers” many budding 
enveloped viruses or viral like particles to the plasma membrane (PM), including 
retroviruses, Ebola, Kaposi sarcoma-associated herpes virus (KSHV) and influenza virus 
like particles (199-200, 215, 291). Vpu-mediated antagonism of tetherin requires an 
interaction between the MSDs of Vpu and tetherin, but as of yet, there is no consensus on 
the precise mechanism by which Vpu modulates tetherin activity.  Vpu has been reported 
to reduce tetherin surface expression by altering the rate of recycled and/or restricting 
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newly synthesized tetherin from reaching the PM (72, 74, 97, 187, 249, 263).  However, 
it has also been reported that Vpu can modulate tetherin activity in the absence of surface 
downmodulation and intracellular depletion (189).  Some studies suggest that tetherin can 
be degraded through β-TrCP mediated targeting to lysosomes or the proteasome (68, 176, 
187).   
 
Although the mechanisms for CD4 and tetherin antagonism are believed to be 
distinct, evidence suggests that Vpu contains some shared features required for 
modulation of both proteins.  For instance, complete proscription of either target requires 
two critical serines housed in the Vpu cytoplasmic tail, which is also required for 
interaction with β-TrCP and degradation of tetherin or CD4 (176, 178, 254). Vpu mutants 
lacking these serine residues retain some activity against tetherin but not CD4 (22, 74).  
Direct parallels between Vpu modulation of tetherin and CD4 are difficult to draw due to 
differences in the assays employed.  Studies investigating tetherin antagonism have relied 
heavily on detection of viral particle release, through protein release or infectious virus 
production, although some studies have also measured tetherin modulation directly.  
Reports on CD4 down-modulation typically rely on biochemical assays measuring total 
protein or surface expression.  Additionally, Vpu studies have used different cell types, 
multiple methods of introducing CD4 or tetherin targets (endogenous or exogenous), and 
different methods of producing Vpu (e.g., native or codon-optimized, contained in the 
provirus or introduced in trans).  Employment of these disparate protocols limits the 
ability to directly compare different studies. 
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We and others found that Vpu prevents GaLV Env incorporation into HIV-1 
particles, likely through a shared structural recognition motif in the Env cytoplasmic tail 
that resembles the critical motif found in the cytoplasmic tail of CD4 (52, 116, 169).  
This sensitivity motif is conserved and is transferrable to confer sensitivity in previously 
insensitive proteins (116).  Based on these findings, we currently believe Vpu recognizes 
GaLV Env as a CD4 analogue.  Like CD4, GaLV Env is packaged into the virus in the 
absence of Vpu, however, unlike CD4, GaLV Env can form infectious pseudotyped virus 
to assess incorporation of the target protein. We therefore used GaLV Env as a surrogate 
for CD4 in infectivity.  Modulation of GaLV Env by Vpu is sensitive and well suited for 
a comparative study with the modulation of tetherin by Vpu.  By employing GaLV Env, 
constraint of both targets can be studied in the same cell type using Vpu encoded in the 
provirus with infectivity as the output for both. 
 
Materials and Methods 
Cell lines. The human endothelial kidney (HEK) 293FT, 293 mCAT-1, and 293 TVA 
(155) cells were obtained from Invitrogen, W. Mothes, and J. Young, respectively.  All 
cells were cultured in DMEM supplemented with 10% fetal bovine serum, 2 mM L-
glutamine, 1 mM sodium pyruvate, 10 mM non-essential amino acids, and 0.5 mg/ml 
G418. 
 
Plasmids.  The NL4-3 derived HIV-CMV-GFP was kindly provided by Vineet 
KewalRamani.  This clade B provirus lacks Env, Vpr, Vpu, Nef, and Vif, and contains a 
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green fluorescent protein (GFP) gene in place of the Nef gene under the control of a 
cytomegalovirus (CMV) promoter.  The gene expressing the far red fluorescent protein 
E2Crimson was engineered into this construct to exactly replace the GFP gene to produce 
HIV-CMV-E2Crimson.  A library of HXB2 Vpu mutants was derived from a previously 
described HXB2 parent Vpu (103).  Mutations to the Vpu gene were generated either by 
linker insertion, or by two-step PCR, and the genes were subsequently subcloned into the 
unique NheI and AscI sites, which were engineered immediately upstream and 
downstream of the natural location of the Vpu gene in HIV-CMV-E2Crimson. The 
human tetherin expression construct tetherin-HA (219) was kindly provided by P. 
Bieniasz. The VSV-G, MLV/GaLV Env, and RSV ΔCT expression constructs have been 
described previously (131, 169).  
 
Infectivity analysis.  293FT cells were plated in 6-well plates and allowed to reach 60% 
confluency prior to transfection.  For tetherin studies, 293FT cells were transfected with 
the following expression constructs: provirus (425 ng) and VSV-G (25 ng) with or 
without 12.5 ng of tetherin-HA in a total of 500 ng.  For GaLV Env assays, cells received 
500 ng provirus, 25 ng of RSV Env ΔCT, and 475 ng MLV/GaLV Env (GaLV Env) 
(116, 169).  Plasmids were transfected with polyethylenimine (PEI) at a concentration of 
1ug DNA per 4ul (1 mg/1 ml stock concentration) and media was replaced 6 hours later.  
At 48h post-transfection, media containing virus was collected and frozen overnight.  For 
tetherin studies, the media was used to transduce 293T mCAT-1 cells expressing the 
murine leukemia virus Env receptor (mCAT-1).  For GaLV Env studies, media was used 
in parallel to transduce both 293 mCAT-1 cells and 293T TVA, which expresses the 
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Rous sarcoma virus receptor (TVA).  Two days later, cells were collected, fixed with 4% 
paraformaldehyde and analyzed by flow cytometry using an Accuri flow cytometer. Cells 
transduced by virus were gated by E2Crimson expression in the FL4 channel to 
determine viral infectivity. 
 
Results 
To determine specific regions of Vpu mediating antagonism of tetherin and GaLV 
Env, we generated a library of HXB2 Vpu mutants and introduced them into a reduced 
HIV-1 clade B proviral construct containing an E2Crimson reporter gene (Figure 4-1A).  
HXB2 Vpu was used, as several mutants had previously been generated (103).  For 
tetherin modulation assays, each provirus was transfected with a VSV-G expression 
plasmid alone, or in combination with an HA-tagged tetherin expression construct, kindly 
provided by P. Bieniasz (219) (Figure 4-1B, left).  Vpu activity was measured by 
comparing infectivity in the presence and absence of tetherin.  For assaying GaLV Env 
modulation, an internally controlled system was used where each mutant was transfected 
with a mixture of plasmids expressing the previously described Vpu-sensitive chimeric 
MLV Env containing the GaLV Env cytoplasmic tail, herein referred to simply as GaLV 
Env, and a Vpu-insensitive Rous sarcoma virus Env lacking the cytoplasmic tail 
(RSVΔCT) (Figure 4-1B, right).  Virus was collected and used to transduce 293T mCAT-
1, expressing the MLV Env receptor (mCAT-1) and 293T TVA, which expresses the 
RSV receptor (TVA).  Vpu activity was measured by comparing the ratio of RSV Env 
pseudotyped infectious virus to MLV Env pseudotyped infectious virus.  For both assays, 
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infections were quantified by flow cytometry, and activity was expressed by normalizing 
to a provirus with wildtype Vpu (Vpu wt) (100% activity) and a Vpu-deficient provirus 
(ΔVpu) (0%).  It should be noted that the raw output is inverted between the two assays: 
with tetherin, Vpu enhances infectivity, but with GaLV Env, Vpu inhibits infectivity. 
 
Restriction is highly dependent on Vpu cytoplasmic tail, but not transmembrane 
region 
Previous studies have demonstrated that Vpu’s transmembrane domain (TMD) 
and cytoplasmic tail (CT) promote tetherin antagonism while only the Vpu CT has been 
identified for GaLV Env restriction (52, 169, 252, 282).  VpuRD, a transmembrane 
“scrambled” mutant, is known to fully restrict CD4, but is ineffectual against tetherin 
(252).  However, there have been conflicting reports about the importance of the TMD in 
CD4 restriction, with some studies suggesting a role of a conserved tryptophan (W22) in 
the C-terminal region (173, 279).  We therefore sought to further investigate the role of 
Vpu’s TMD by employing two previously described TMD mutants: VpuRD and W22L 
(173, 251-252).  We introduced both of these mutants into our proviral system and tested 
their activity against tetherin and GaLV Env (Figure 4-2).  As previously reported, both 
VpuRD and W22 mutants had decreased activity against tetherin (264, 282-283).  
However, both mutants exhibited wildtype activity against GaLV Env.  In addition, we 
also included serine to alanine mutations at positions 53, 57.  These serines are highly 
conserved and have been previously reported to be essential in tetherin and CD4 
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downmodulation (256, 282).  As expected, the serines are important in downmodulation 
of both targets, presumably through their ability to mediate β-TrCP activity. 
 
Vpu localization restricts antagonism of tetherin and GaLV Env 
The subcellular location where CD4 and tetherin are targeted appears to be 
distinct.  While action against CD4 has been reported to be exclusively in the RER, 
action against tetherin is generally believed to occur in a post-ER compartment (75, 175, 
244, 263, 284).   Previous studies demonstrated that Vpu retention in the RER by the 
addition of a putative retrieval motif prevents downmodulation of tetherin at the PM 
(283-284).  We found that placement of the KKDQ ER-retention motif on the C-terminus 
of Vpu, exactly as previously described (284), reduced its ability to restrict either target, 
though the effect on tetherin restriction was more severe.  These data are consistent with 
direct or indirect interactions between Vpu and both target proteins in a post-ER region.  
 
Conserved amino acid features in Vpu cytoplasmic tail are required for activity 
Next, we generated truncation mutations in Vpu to determine the minimal 
sequence required for modulation of the two targets in this system.  For both tetherin and 
GaLV Env, truncation beyond 13 C-terminal amino acids (Δ13) resulted in a decrease in 
Vpu function, although for tetherin this decrease was progressive (Figure 4-2). To 
identify critical regions upstream of Δ13, we mutated two residues at a time to alanine 
and assayed for activity.  For both targets, Vpu was most sensitive to mutations within 
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the conserved hinge region while upstream regions were less sensitive (Figure 4-3A).  
Unlike reported findings for BH10 Vpu R30A,K31A (75), mutations located within the 
YRKIL trafficking motif, we did not observe a decrease in infectivity in the presence of 
tetherin with our HXB2 Vpu system.  Although both are subtype B, variances in amino 
acid sequence between the Vpus may explain differences.   
 
We then sought to identify specific amino acids required in the CT by scanning 
individual point mutants through substitution of alanine for individual amino acids, with 
the exception of alanine which was substituted with serine.  Interestingly, almost all 
amino acids within the Vpu-hinge region between amino acids 51-60, not solely the 
serines 53, 57, were sensitive to disruption (Figure 4-3B).  A recent report suggested that 
a putative trafficking motif, EXXXLV, located between residues 60-65 is required for 
tetherin antagonism (146).  In agreement with this report, we found that E60A disrupted 
tetherin activity, but the effects of L64A, and V65A alone were more modest. These 
results demonstrate Vpu’s requirement for conservation of the hinge region for 
antagonism of two distinct protein targets.  Because alanine substitution should not affect 
physical accessibility of the hinge region by proteins such as β-TrCP, we presume that 
modification of the conserved features, such as the acidic amino acids, disrupts 
recognition of Vpu by cellular factors or Vpu’s ability to interact with targets.        
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DISCUSSION 
Here we have identified shared critical features in Vpu required for restriction of 
two distinct proteins, tetherin and the glycoprotein GaLV Env.  With the exception of the 
TMD region, Vpu requires similar features to counteract both targets.  Our Vpu screen 
raises the question: why are similar features in Vpu required for modulation of two 
disparate target proteins?  We propose that Vpu utilizes multiple regions for three 
somewhat overlapping steps in both restriction pathways: i) retention through interaction, 
ii) modification and redirection, and iii) degradation.  In the case of tetherin, interaction 
occurs between the TMDs and for CD4 interaction occurs in the CTs and is absolutely 
required for antagonism (74, 112, 240, 252, 283).  The importance of TMD interactions is 
highly evident in the evolution of species and subtype specificity of Vpu antagonism of 
tetherin (138, 248, 284).  In the second step, we postulate that Vpu’s CT-hinge region is 
required for both tetherin and GaLV Env modification and redirection.  The hinge region 
likely represents a collective β-TrCP recognition motif, with serines housed within a 
conserved acidic stretch of amino acids.  How Vpu modifies and subsequently redirects 
targets is not yet fully understood, although emerging data suggests a role of 
ubiquitination of both tetherin and CD4.  While CD4 is polyubiquitinated, it is currently 
unclear whether tetherin is multiply monoubiquitinated or polyubiquitinated, hallmarks of 
redirection for lysosomal or proteasomal degradation, respectively (93, 175, 215, 280).  
In the final step of restriction, degradation of targets may occur.  CD4 is directed for 
degradation through ERAD-proteasomal targeting (29, 48, 178, 251, 297, 300),  
However, the role of degradation for tetherin is unclear, with some data suggesting 
lysosomal (68, 93, 187) or proteasomal degradation (176).  Interestingly, although 
117 
 
tetherin restriction can occur independently of the degradation, possibly through 
retention-based interactions, recent work demonstrates a significant role for lysosomal 
degradation of newly synthesized tetherin (72).  We suspect that degradation may 
represent a late stage in restriction and may not be required until available Vpu becomes 
saturated. 
 
Through our systematic alanine mutagenic library of the Vpu cytoplasmic tail, we 
identified specific amino acids contributing to the antagonism of two distinct targets, 
tetherin and a CD4 analogue, GaLV Env.  Interestingly, we demonstrated a role for 
multiple amino acids within the CT hinge region and the importance of Vpu localization 
in restriction.  Altogether our findings, along with other mutagenic Vpu studies, suggest 
that Vpu has unique regions mediating interaction with targets, while it uses conserved 
features within the CT to ultimately redirect and potentially degrade target proteins.   
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Figure 4-1. Schematics of HIV-1 proviral construct and experimental assay 
(A) HIV-1 HXB2 proviral construct with E2Crimson reporter showing enlargement of 
Vpu schematic outlining critical features in Vpu.  Dotted outline predicted α-helices 
(103), bold script indicates the hinge region and underlined script highlights 
phosphorylated serines at positions 53,57.  (B) For tetherin assays, 293FT cells 
(Invitrogen) were transfected with the following expression constructs: provirus (425 ng) 
and VSV-G (25 ng) with or without 12.5 ng of tetherin (kindly provided by P. Bieniasz) 
in a total of 500 ng.  For GaLV Env assays, cells received 500 ng provirus, 25 ng of RSV 
Env ΔCT, and 475 ng MLV/GaLV Env (GaLV Env) (116, 169).  At 48hr post-
transfection, media was frozen overnight and used to infect target cells.  Infected cells 
were fixed and analyzed by FACS on an Accuri flow cytometer.  Flow plots illustrate 
typical data output for positive controls. 
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Figure 4-1: Schematics of HIV-1 proviral construct and experimental assay 
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Figure 4-2: Features required for Vpu-mediated antagonism of targets 
Tetherin (dark bars) and GaLV Env (light bars).  (Top) Location of VpuRD, W22L 
(bold), critical serines 53, 57 (underline) and truncations (arrows) are noted in the Vpu 
schematic.  (Bottom) Relative Vpu activity is shown as mean averages (n=3-4, +SE) 
calculated by normalizing infectious units per ml for each mutant Vpu relative to Vpu 
wildtype (Vpu wt) (100%) and no Vpu (ΔVpu) (0%). 
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Figure 4-2: Features required for Vpu-mediated antagonism of targets 
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Figure 4-3. Alanine mutagenic scan of Vpu reveals antagonistic regions for 
downmodulation of tetherin and GaLV Env 
Tetherin (dark bars) and GaLV Env (light bars). Amino acids were mutated to alanine, 
with the exception of alanine which was mutated to serine (A) A double alanine-
mutagenic scan was performed on the cytoplasmic tail region of Vpu (double mutations, 
underlined).  (B) An individual amino acid alanine scan was analyzed for amino acids 
identified in the double-alanine scan (bold, underlined) and relative Vpu activity was 
measured.  Relative Vpu activity is shown are mean averages (n=3-4, +SE) calculated by 
normalizing infectious units per ml for each mutant Vpu relative to Vpu wildtype (Vpu 
wt) (100%) and no Vpu (ΔVpu) (0%). 
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Figure 4-3: Alanine mutagenic scan of Vpu reveals antagonistic regions for 
downmodulation of tetherin and GaLV Env
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V. Hydrophobicity of membrane spanning domain of Env dictates 
fusogenicity, but not Env recruitment to viral particles 
 
Sanath Kumar Janaka, Devon A Gregory and Marc C Johnson 
 
Abstract 
Non- native viral glycoproteins, including Friend murine leukemia virus (F-MLV) 
envelope (Env) are actively recruited to HIV-1 assembly sites by an unknown 
mechanism. Because HIV-1 Gag is a membrane binding protein that could modify the 
local membrane environment, we wanted to examine the contribution of the Env 
membrane spanning domain (MSD) in MLV Env recruitment to budding viruses. To 
examine the importance of MSD hydrophobicity in Env recruitment, a series of mutant 
MLV Env genes were constructed that added or deleted one, two, or three leucines in the 
MSD. -1L, -2L, -3L, +1L and +2L mutations did not prevent Env incorporation into HIV-
1 particles, but abolished fusogenic activity and infectious particle production.  
Surprisingly, +3L Env was able to produce infectious particles and was constitutively 
fusogenic.  However, when the CTD of Env was deleted, the MSD mutants partially 
regained the ability to produce infectious particles.  Further mutational analyses revealed 
that the first 10 amino acids of the CTD is a critical regulator of infectivity. A similar 
phenotype was observed in HIV-1 Env upon addition of leucines in the MSD, with +1 
and +2 Leucine mutations greatly reducing Env activity, but +3 Leucines behaving 
125 
 
similar to wildtype. Unlike MLV Env (+1L, +2L), HIV-1 Env (+1L, +2L) infectivity was 
not restored by deletion of the CTD. We hypothesize that the fusion incompetency 
observed with many of the mutants arises from the torsion on the Env upon addition or 
deletion of the leucines, except in the case of +3L Env. With the +3L Env, an extra 
helical turn would be added in the MSD and this may be sufficient promote fusogenic 
activity. 
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Introduction 
Enveloped viruses assemble by the confluence of structural proteins, genetic 
material and surface glycoproteins. Glycoprotein-deficient viruses have the potential to 
be complemented by diverse, non-native glycoproteins in a process termed pseudotyping 
[reviewed in (60, 121, 182, 214)]. The molecular mechanisms underlying the recruitment 
of foreign glycoproteins to budding viral particles are not understood. However, such 
pseudotyped viruses can be used as a gene delivery tool to direct viruses to a specific cell 
type (12, 65, 95, 134, 181, 213).  
 
Retroviral Env glycoproteins are produced as precursors that trimerize in the 
endoplasmic reticulum (ER). Subsequently, the precursor protein is cleaved into its 
constituent sub-domains, namely, the surface subunit (SU) and transmembrane subunit 
(TM) by furin or a furin-like-protease. The mature Env is thus a trimer of heterodimers, 
composed of the SU, containing the receptor binding domain and TM containing the 
fusion peptide. SU and TM are held together by an inter-subunit disulphide bond in the 
case of alpha-, gamma-, and delta-retroviruses (80, 122, 152, 208, 223, 225); and non-
covalently associated in the case of lenti- and beta-retroviruses (102, 143). Upon receptor 
binding by SU, several conformational changes take place in Env, promoting co-receptor 
binding and/or accession of the host cell membrane by the fusion peptide in TM (76). A 
functional Env can deliver the viral components to the host cell, post fusion.. In the case 
of gammaretroviruses, fusion is controlled by the C-terminal cytoplasmic tail domain 
(CTD) of Env and isomerization of disulphide bond between SU and TM (164, 289). The 
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C-terminus of these glycoproteins contains a short peptide (R-peptide) that is cleaved by 
the viral protease during or shortly after viral assembly.  The presence of the R-peptide at 
the C-terminus of Env prevents fusogenic capability of the Env (145, 157, 164, 234-235, 
276, 306). Cleavage of the R-peptide allows for receptor dependent fusion of the Env to 
the target cell (100, 235). Recent cryo-EM imaging data suggests that the CTD of MLV 
Env holds the MLV Env ectodomain in a tight conformation, but upon cleavage of the R-
peptide, the TM legs are splayed and this allows fusogenic activation of Env (165). 
 
Glycoprotein acquisition by retroviral particles is not well understood and the 
physical factors that contribute to this recruitment have not been defined, but multiple 
viral glycoproteins have been reported to efficiently pseudotype retroviral particles 
[reviewed in (60, 121, 214)]. Not every glycoprotein-virus pair results in infectious 
particles, but the recruitment of such a variety of surface proteins would indicate the use 
of a common mechanism by the virus to obtain its compatible glycoprotein. Some reports 
indicate a direct interaction between the N-terminal matrix (MA) of Gag and the CTD of 
Env may promote packaging of Env into viral particles (88, 177, 194, 211). In the case of 
HIV-1, several studies have shown the MA domain of HIV-1 Gag to be required for HIV-
1 Env incorporation into budding viral particles. For instance, compensatory mutations in 
MA of HIV-1 have been selected for when paired with incorporation defective HIV-1 
Env mutants (194), suggesting a direct interaction between HIV-1 MA and the HIV-1 
Env CTD. However, infectious HIV-1 viral particles can still be produced when the 
entire CTD of HIV-1 Env is deleted, and in some cases such CTD truncations are 
naturally selected for when lentiviruses are passaged in tissue culture (42, 129, 141-142, 
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261-262).  Furthermore, we have demonstrated previously that MLV Env with its CTD 
deleted is efficiently recruited to HIV-1 assembly sites (168). Contrasting evidence has 
been presented by Muranyi et al., and they have recently shown that in the case of HIV-1 
Env, truncation of the CTD leads to non- specific recruitment of Env to Gag budding 
sites (196) Thus, direct interactions between MA and the glycoprotein CTD are not the 
sole factors dictating glycoprotein recruitment to viral assembly sites (10, 88, 177, 194, 
211). To understand Env recruitment further, we chose to examine the contribution of the 
MSD in MLV Env to glycoprotein trafficking and fusogenicity.  We hypothesized that 
the hydrophobicity of the MSD of Env would contribute to the trafficking of Env to viral 
particles.  We chose to focus on a stretch of ten continuous hydrophobic amino acids in 
the MLV Env MSD (Figure 5-1). To understand if this hydrophobic region in the MSD of 
Env contributes to recruitment of the glycoprotein to viral particles, we engineered the 
addition or deletion of 1, 2 or 3 leucines to modulate the hydrophobicity of the MSD. 
Biochemical and infectivity assays were performed to understand recruitment of Env; 
cell-to-cell fusion assays were performed to understand the effect of the mutations on the 
fusogenicity of Env.  
 
Materials and Methods: 
Plasmids 
The F-MLV Env and YFP tagged F-MLV Env expression constructs were a kind gift 
from Dr. Walter Mothes (Yale Unviersity). The Leucine addition/ deletion mutations in 
the MSD in F-MLV Env were created by inserting linkers carrying the appropriate 
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mutations in the region of the Env coding DNA between BclI and ClaI sites in the YFP 
tagged Env construct. The corresponding untagged Env constructs were created by 
digestion and ligation of the PasI to EcoRI segment to the WT F-MLV Env construct. 
Constructs expressing the truncated form of the F-MLV Env were created by introducing 
stop codons at the appropriate positions in the linker replacing the fragment between ClaI 
and EcoRI. Alanine scanning mutations in the context of the 21 construct was created 
by linkers carrying the appropriate mutations and replacement of the fragment between 
ClaI and EcoRI. The HA tagged F-MLV Env was created by replacement of the DNA 
fragment encoding YFP with that encoding the HA tag (YPYDVPDYA). The B- clade 
consensus, codon optimized pcDNA 3.1 HIV-1 gp160 expression construct was a kind 
gift from Dr. Beatrice Hahn (University of Pennsylvania). Leucine addition mutants in 
the MSD of HIV-1 Env were introduced by overlap extension PCR, with the primers 
carrying the appropriate mutations and replacement of the fragment of DNA between 
PasI and BamHI. HIV-1 Env CTD truncation mutants were created by introducing the 
stop codon after RVRQGY, a truncation removing 144 amino acids in the HIV-1 Env 
WT Env. Primers carrying the mutation were used in PCR amplification and replacement 
of the fragment between BamHI and BsrGI.  
 
NL4-3 derived HIV-CMV-GFP was kindly provided by Vineet KewalRamani (National 
Cancer Institute-Frederick). This proviral vector lacks the genes encoding Vif, Vpr, Vpu, 
Nef and Env and has a CMV immediate-early promoter driven GFP in the place of Nef. 
A vector expressing HIV Gag with the late domain (PTAP) changed to alanines (HIV 
Gag PTAPAAAA) was previously described (132). 
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The lentiviral vector with a CMV driven, reverse intron-interrupted Gaussia Luciferase 
was a gift from David Derse. The reporter gene with the intron was amplified and 
dropped into the HIV-CMV-GFP vector in the appropriate orientation by PCR and 
replacement of the DNA fragment between NotI and XhoI, encoding the CMV driven 
GFP. Only the infected cell, but not the transfected cell, can produce an intact luciferase 
protein, leading to signal specifically from an infection (8, 183).   
 
The tet-off expression plasmid was created by introducing the gene encoding the tTA 
(Tet-Off) protein into a pQCXIP vector (Clontech) between NotI and BamHI sites, 
downstream of the CMV immediate early promoter. The retroviral transfer vector, retro-
tight-X-hygro from Clontech was used to create a TRE driven Gaussia luciferase (GLuc) 
inducible expression construct (TRE-GLuc). Specifically, the gene coding for the 
Luciferase protein from the marine organism, Gaussia princeps, was introduced between 
BamHI and NotI sites downstream of the Tetracycline response element (TRE).   
 
Cell culture 
The 293FT cell line was obtained from Invitrogen. The cell line expressing the ecotropic 
F-MLV Env receptor, 293T mCAT-1, was kindly provided by Walther Mothes. The 
293T TVA cell line expressing the receptor for Rous sarcoma virus (RSV) Env was 
provided by John Young (Scripps Research Institute) (156). TZM-bl cells were obtained 
from the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH.  
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The following procedure was used to create 293T mCAT-1 cells with a stably integrated, 
tet-off inducible Gaussia Luciferase reporter system. 293FT cells were transfected with 
constructs expressing MLV GagPol, TRE-Gluc (Also codes for hygromycin resistance 
gene) and VSV-G. The supernatant from this transfection was used to infect 293T 
mCAT-1 cells. The cells were selected for Hygromycin expression. Further, clonal 
isolates were obtained by following a procedure of limiting dilution. Six clonal 
populations were tested. Two cell lines were selected for further assays based on level of 
induction of the reporter and the presence of the mCAT-1 receptor.  
 
All HEK based cell lines were maintained in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 10% fetal bovine serum, 2 mM glutamine, 1 mM sodium 
pyruvate, 10 mM non-essential amino acids, and 0.5 mg/ml G418. In phases of cell 
culture involving transfection or transduction, G418 was not added to the medium. TZM-
bl cells were maintained in DMEM supplemented with 10% fetal bovine serum, 2mM 
glutamine and 1% MEM vitamins.  
 
Infectivity assay 
293FT cells were transfected with 500ng of HIV-CMV-GFP and 500ng of the wildtype 
(WT) or mutant F-MLV Envs using 4g of Polyethylenimine (PEI) per microgram of 
DNA (31). For transfections with HIV-1 Env and its mutants, 950 ng of HIV- CMV- 
GFP and 50 ng of the WT or mutant HIV-1 Envs were transfected into 293 FT cells. The 
media was changed 6-12 h later to remove the residual transfection reagent. Supernatant 
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was collected 24 h after the media were exchanged and then frozen at -80
o
C for at least 2 
h to lyse any cells in the supernatant. The supernatant was thawed in a 37
o
C water bath 
and spun at 1500 g for 10 min to pellet any cells or cell debris. 500l of the supernatant 
was applied to fresh 293T mCAT-1 cells in a 12 well plate for transfections with MLV 
Env. For transfections with HIV Env, 500l of the supernatant was added to TZM-Bl 
cells along with Hexadimethrine Bromide to a final concentration of 80g/ml (56). Cells 
were collected 48 h later, fixed with 4% paraformaldehyde, and analyzed by the Accuri 
C6 flow cytometer system. Data were analyzed by Accuri C6 software.  
 
Western Blots 
Transfections for western blots were performed as described for infectivity assays. HA 
tagged F-MLV Env derivatives were used for analysis by western blotting. Viral samples 
were pelleted through a 20% sucrose cushion. The residual serum was removed by 
washing the pellet with PBS. The pellets were resuspended in 2X SDS-PAGE loading 
buffer and the equivalent of 1ml of viral supernatant was analyzed by 10% discontinuous 
SDS-PAGE. Cell samples were prepared in 1X SDS-PAGE loading buffer and 5-10% of 
the total amount of cells was analyzed in parallel with the viral supernatants. Proteins 
were transferred manually onto a 0.45 m PVDF membrane. The membrane was blocked 
with 1% non- fat dried milk in PBS-Tween20 and probed with mouse anti HA antibody 
diluted 1:1000 (Sigma) and mouse anti-HIV p24 hybridoma medium diluted 1:500 
(obtained through the AIDS Research and Reference Reagent program, Division of 
AIDS, NIAID, NIH: HIV-1 p24 hybridoma [183-H12-5C]) from Bruce Chesebro (49). 
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Blots were then probed with horseradish peroxidase conjugated anti-mouse antibody 
(Sigma) diluted 1:10000. Luminata Classico western HRP substrate from Millipore was 
used for visualization of the membranes on a chemiluminescence image analyzer, 
LAS3000 from Fujifilm. Blots were also probed with IR dye 700DX anti mouse IgG and 
visualized using Odyssey infrared imaging system from LI-COR biosciences. 
 
Viral Capture Assay 
293FT cells were transfected with 900ng of HIV provirus with the intron interrupted 
Guassia Luciferase reporter, 25 ng of Rous Sarcoma Virus (RSV) Env CTD and 75 ng 
of YFP tagged F-MLV Env or its mutants as described previously. 96 well ELISA plates 
(Corning) were coated with polyclonal anti-GFP antibody from rabbit diluted 1:5000 in 
ELISA coating buffer, overnight at 4
0
C. The antibody was removed and replaced with 
ELISA blocking buffer for 1 h at room temperature. 50l of viral samples were incubated 
in the wells after removal of the blocking buffer for 4 h. The wells were then washed with 
PBS and 10000 cells of 293T mCAT-1 or 293T TVA cell lines were added to the wells. 
The experiments were done with or without antibody with both cell lines. Direct 
transductions of the above mentioned cell lines were also performed.  
 
Scanning Electron Microscopy 
Correlative SEM was performed as previously described (132, 151). Briefly, 293T 
mCAT-1 cells were plated onto glass coverslips with a thin-layer gold coat in a grid 
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pattern and transfected with 800ng of HIV Gag PTAPAAAA and 200ng of YFP-
tagged MLV Env or one of its mutants using PEI as described earlier. Transfected cells 
were mapped by fluorescence microscopy. Anti-GFP 20 antibody (G6539; Sigma) was 
used to label YFP-tagged MLV Env. Gold-labeled anti-mouse secondary was obtained 
from Jackson Laboratories (catalog no. 115-205-146). After critical point drying and 
carbon evaporation coating, samples were imaged with a Hitachi S4700 FE SEM at the 
University of Missouri Electron Microscopy Core Facility. 
 
Cell-to-cell fusion assay 
293FT cells were transfected with 500 ng of tet-off expression plasmid and 500 ng of an 
Env expression construct. The media was changed 6-12 h post transfection to remove any 
residual transfection reagent. 100000 of the transfected cells were co-cultured with an 
equal number of 293T mCAT-1 TRE G Luc cells for 48h. 20l of the supernatant on the 
co-cultured cells were assayed in duplicate for G Luc with 50
in 0.1M Tris, pH 7.4 and 0.3M sodium ascorbate. Each experiment was performed along 
with WT F-MLV Env for a negative control, Filler DNA in the place of Env for another 
negative control and also with F-MLV Env lacking the R-peptide (F-MLV R) as a 
positive control. All data were normalized to F-MLV R Env fusogenicity. 
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Results 
Assembly of Gag at the inner leaflet of the plasma membrane has been proposed to 
modify the local lipid composition of the bilayer and this may promote further 
recruitment of transmembrane proteins- either native viral or non-native glycoproteins 
(144, 206). This hypothesis would indicate the MSD of Env plays a critical role in the 
recruitment process. The MSD of F-MLV Env contains a string of ten uninterrupted 
highly hydrophobic amino acids (Figure 5-1). While MSDs are always composed of 
hydrophobic amino acids, this continuous stretch of exclusively hydrophobic amino acids 
represents the extreme of hydrophobic domains.  
 
Addition or removal of leucines in the MSD of F-MLV Env affects the production of 
infectious viral particles 
We hypothesized that the hydrophobic region in the F-MLV Env would contribute to its 
recruitment to viral particles. To test this hypothesis, the MSD was mutated to contain 1, 
2 or 3 fewer or additional leucines (termed -3L, -2L, -1L, +1L, +2L, +3L, respectively; 
WT Env is termed ‘0L’) within the hydrophobic block of amino acids, highlighted in 
Figure 1. Leucine, being a hydrophobic amino acid, would be expected to change the net 
hydrophobicity of the MSD in addition to changing the MSD length. Initially, infectivity 
of an Env-defective HIV-1 provirus (HIV-CMV-GFP) co-transfected with these Envs 
was tested.  We expected many of these Env clones, particularly those with large 
changes, to be non- functional. Surprisingly, functionality among these mutants did not 
appear to be correlated with hydrophobicity of the MSD. Only WT Env (0L) and +3L 
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Env were able to generate infectious particles with HIV-1 cores, all others were non-
functional in infectivity assays (Figure 5-2A).   In addition to this approach, we also 
altered the hydrophobicity of the MLV Env by replacement of three leucines in the 
hydrophobic core of the MSD to three isoleucines (same hydrophobicity) or three 
alanines (decreased hydrophobicity). In such cases, where the length of the MSD was not 
affected and hydrophobicity was altered, the infectivity was equivalent to WT F-MLV 
Env and again showed that the hydrophobicity of the Env MSD did not determine Env 
recruitment (Figure 5-S1).  
 
MSDs of transmembrane proteins usually assume a helical conformation and secondary 
structure prediction algorithms predict the F-MLV Env MSD to be helical (36, 70). Since 
addition of three Leucines would introduce a turn in the helix, this could explain why this 
was the only mutant with significant activity.  To explore this further, two additional 
mutants with Four (+4L) or five (+5L) Leucines added to the MSD was assayed for 
infectivity (Figure 5-S2). While +4L mutant was non-infectious, +5L mutation partially 
restored infectivity to the Env, suggesting that the helical orientation of the MSD 
contributes to Env functionality.  Because +4L and +5L did not regain function, the 
remainder of the study focused on mutant -3L to +3L.  
 
Leucine additions or deletions do not affect viral incorporation of Env 
To determine if the changes in the transmembrane domain affect the incorporation of Env 
into viral particles, western blotting was carried out on cell lysate and viral supernatant 
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from cells expressing each mutant Env along with HIV-CMV-GFP.  The HA epitope tag 
(YPYDVPDYA) was introduced into the mutant Envs in the variable region of the 
proline rich region, a region in MLV Env where insertions of peptides are tolerated 
without any effect on Env function (79, 241, 302).  F-MLV Env is produced as a gp85 
precursor and processed by a cellular protease into gp70 (SU) and p15 (TM)(201). In the 
case of mutants -1L, -2L, -3L, and +2L there was a noticeable reduction in amount of 
processed Env. However, all seven of the Env proteins were incorporated into viral 
particles at equivalent levels.  Unexpectedly, transfected cells expressing mutants -1, -2, 
and -3 released some processed and unprocessed Env in a pelletable form even in the 
absence of the structural proteins.  Addition of HIV-1 GagPol to the transfection 
increases the amount of both processed and unprocessed Env released into the media 
(Figure 5-2B).   
 
To rule out any ambiguities in the incorporation of Env into viral particles, we performed 
an alternative infectivity based assay to quantify Env incorporation into viral particles.  
For this assay, outlined in Figure 5-3A, particles are produced in the presence of one of 
the mutant MLV Env proteins as well as Rous sarcoma virus Env CTD, which we 
demonstrated previously to be randomly incorporated into HIV-1 particles (132).  These 
particles are adhered to a tissue culture plate with an antibody against MLV Env and 
unbound virus is washed away.  Bound virus is then overlaid with 293-TVA cells, which 
are susceptible to fusion with RSV Env, but not MLV Env.  Thus, infectivity of the 293-
TVA cells reflects incorporation of MLV Env into particles.   
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An MLV Env construct with YFP engineered into the proline rich region was used for 
this assay because we have found that the YFP tag in MLV Env works well for viral 
capture with a polyclonal anti-GFP antibody.  Each of the mutants was engineered with 
YFP and assayed to see if their phenotype was altered by the presence of YFP.  For this 
assay an Env-defective HIV-1 provirus containing Gaussia luciferase with a reverse 
intron (HIV-CMV-iGLuc) was used (8, 183).  As expected, infectivity on cells with the 
receptor for MLV Env (293T mCAT-1) was highest with MLV Env 0L and +3L (Figure 
5-3B, straight infection).  With this assay it was apparent that some infectivity occurred 
with all of the Env mutants, but -1L, -2L, -3L, +1L, and +2L were all reduced about 100-
fold compared to wildtype and +3L. This infectivity with the YFP-tagged mutants 
followed the same pattern as the untagged Envs (Compare Figure 5-2A and Figure 5-3B).   
Next we tested if the viral particles could be adhered with the GFP antibody.  Virus was 
adhered to the plate and washed prior to infection as outlined in Figure 5-3A.  GLuc 
signal equivalent to that from the straight infection was observed with each of the 
mutants, and the signal in each case was greatly diminished in controls with no antibody.  
Note, the infectivity in the control wells with no antibody containing the 0L and +3L 
Envs appeared high compared to the poorly functioning glycoproteins, but this signal was 
still 100-fold lower than the equivalent wells that did contain antibody. Next we tested 
infectivity on cells susceptible to infection with the RSV Env to determine if any of the 
mutant glycoproteins were incorporated and capable of facilitating viral capture. Direct 
transduction of 293T TVA cells with the viral supernatant showed the presence of 
infectious viral particles in the supernatant from all transfections. Infectivity by virus 
capture against the YFP tag followed by infection on 293 TVAs was comparable in all 
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samples containing the YFP tagged F-MLV Env or a mutant thereof.  This experiment 
confirms that leucine mutants in F-MLV Env are incorporated to similar levels into viral 
particles.  
  
 Several cellular proteins are incorporated into HIV particles by virtue of their 
abundance at the site of viral budding (210), which may also be the case with non-native 
viral glycoproteins. MLV Env recruitment to viral particles however has been shown to 
be specific using a correlative SEM imaging technique (151, 168). Since MSD mutants 
may change the trafficking and characteristics of the Env, we wanted to understand if the 
mutation affected the specific recruitment phenotype. In 293T mCAT-1 cells, when late 
domain defective, HIV Gag PTAPAAAA was expressed, YFP-tagged +1L MLV Env 
was specifically recruited to viral budding sites (Figure 5-S3). The hydrophobicity 
changes in Env therefore do not affect recruitment of MLV Env to HIV budding sites.  
 
Addition/deletion of Leucines in MSD of F-MLV glycoprotein affects fusogenecity of 
Env 
Because incorporation of the Leucine insertions and deletions did not affect 
incorporation into particles, we questioned why they were non-functional.  To understand 
the infectivity phenotype with these mutants, we tested the fusogenicity of each mutant 
Env. Because Gammaretroviral Env proteins are fusogenically inactive prior to cleavage 
of the R-peptide, each of the Env mutants was engineered to have the R-peptide removed 
and the fusogenicity of each mutant (with or without the R-peptide) was assayed.  
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Briefly, each mutant Env was transfected along with a tet-off expression construct into 
293 FTs. 24 h post transfection, 100,000 of the transfected cells were co-cultured with 
100,000 293T mCAT-1 cells expressing TRE driven GLuc (See materials and methods). 
If Env is fusogenic, the transfected cells and the receptor expressing cells fuse, resulting 
in a tet-off dependent induction of GLuc. The extent of induction of the reporter relative 
to the WT Env and the R Env indicates the fusogenicity of the Env. The mutant full 
length (FL) Envs, regardless of mutations in the MSD were found to be non-fusogenic by 
this assay, with the exception of +3L Env. The +3L Env is constitutively fusogenically 
active despite the presence of the R-peptide (Figure 5-4A). Upon deletion of the R-
peptide, the 0L and +3L Envs were the most fusogenic, but most of the R Env mutants 
displayed some fusogenic activity. Because the R mutants were at least partially fusion 
capable, we tested this panel of mutants for the ability to form infectious particles.  With 
the exception of the wild type and +3L mutants, the leucine mutants remained non-
infectious despite having the R-peptide deleted (Figure 5-4B).  Finally, we tested whether 
there are additional sequences upstream of the R-peptide that act as negative regulators of 
fusion by engineering the leucine mutants with the majority of their cytoplasmic tail 
deleted (25 mutants). In each case, the infectivity with the truncated Env was higher 
compared to the infectivity with the respective FL Envs (compare Figure 5-4B and Figure 
5-2A). The mutant -2L 25 Env did not produce a high level of infectious particles and it 
may relate to the level of the mature Env with this mutant as seen in the case of -2L FL 
Env (Figure 5-2B). Having thus implicated the CTD in this observed phenotype, we 
wanted to determine the sequences in the membrane proximal region of the CTD 
responsible for modulating infectivity in the MSD mutants.  
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Sequences in the CTD contributing to infectivity with MSD mutations in Env 
While removal of most of the CTD (25) restored infectivity to most of the MSD 
mutants, removal of the R-peptide did not.  This suggests that the sequence just proximal 
to the MSD can modulate fusogenic activity.  MLV Env is trimeric in the ectodomain and 
also is modeled to be trimeric in the CTD prior to R-peptide cleavage (80, 165, 276).  A 
recent study by Loving et al. (165) demonstrated that the membrane proximal ectodomain 
of MLV Env is tightly packed, but in the absence of the R-peptide, the TM legs are 
splayed apart. These pieces of data led us to hypothesize that the CTDs in the MSD 
mutants form a tight trimer that prevents fusion unless the majority of the CTD is deleted.  
To identify the minimum portion of CTD that negatively regulated fusion of the MSD 
mutants, we created truncations in the 0L and +1L Env. These Envs are processed 
efficiently in the cell; they are incorporated into viral particles and are non-fusogenic 
with FL CTD. However, whereas the +0L Env can produce infectious particles regardless 
of its CTD, the +1 can only produce infectious particles if its CTD is deleted.  Exploiting 
the singular difference in the infectivity with these two Envs, we explored the sequences 
required for fusion control and modulation of infectivity. Initially, truncations in the CTD 
removing 21, 22, 23 or 24 amino acids were made in the 0L and +1L Envs. The 
infectivity of HIV-1 particles with these Envs showed that removal of 23 C-terminal 
amino acids in the CTD of the +1L Env allowed infectious particle production (Figure 5-
5A).  
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To test whether the amino acid sequences N-terminal to position 21 were involved 
in the modified infectivity and fusogenicity, amino acids between positions 21 and 29 
were mutated to alanine as sequential double mutants or single point mutants in the 
context of an Env 21 mutant.  Mutation of F28, either as a part of a double substitution 
or as a point substitution, reduces infectivity drastically to 0L Env 21 and +1L Env 21.   
Mutations of amino acids R24 and D25 restored infectious particle production to +1L 
Env 21, while other mutations in this section of eight amino acids did not change its 
phenotype (Figure 5-5B).  Mutation of R24 or D25 alone has a less significant affect 
(Figure 5-5C).  In the case of all other mutations, 0L Env is not affected in its capacity to 
produce infectious pseudotyped HIV-1 virus (Figure 5-5B and C).  To test if the RD23, 
24AA mutation was sufficient to restore Env function to the +1 Env in the context of the 
FL CTD, the mutation was recreated in the FL 0L and +1L Envs and tested for infectivity 
(Figure 5-5B). Mutation of these two residues was not sufficient to restore infectivity in 
the context of the FL CTD.  In fact, mutation of these residues also drastically reduced 
infectivity of the +0 FL Env.  Thus, these two residues are important contributors to Env 
regulation, but are not the only residues required to negatively regulate Env function.    
 
HIV-1 Env MSD hydrophobicity does not dictate Env recruitment and infectivity 
modulation is independent of the CTD:  
With the F-MLV Env, fusion regulation is achieved by sequences in the CTD and 
hence helical torsion of Env may affect the fusogenicity of the Env in a CTD dependent 
manner. While HIV-1 Env is activated for fusion upon HIV-1 protease activation and 
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viral maturation, there is no proteolytic cleavage of the Env itself (303-304). To 
understand if this infectivity phenotype was restricted to Envs processed by protease for 
fusion activation, we examined HIV-1 Env. Leucine addition mutations in the MSD HIV-
1 Env were created and the infectivity was assayed in each case. Similar to MLV Env, 
addition of one or two leucines in the MSD prevented infectivity, while WT and +3L 
HIV-1 Env were infectious (Figure 5-6). Further, the CTD of each of the Leucine 
addition mutants in HIV-1 Env was deleted to understand the role of the CTD in this 
phenotype for a non-proteolytic fusion controlled Env. The HIV-1 Env CTD truncation 
mutants behaved similar to their FL counterparts indicating that although MSD 
hydrophobicity may affect function of Env, the CTD is not required for this modulation 
(Figure 5-6).  
 
Discussion 
We have shown previously the active recruitment of foreign glycoproteins to 
HIV-1 budding sites (132). Further studies into protein domains in MLV Env required for 
recruitment to HIV-1 assembly sites showed that the cytoplasmic tail domain was not 
required for specific recruitment (168). Furthermore, Gag domains contribute to selective 
recruitment of foreign glycoprotein to sites of viral egress and MA is dispensable for such 
Env recruitment (91). Gag being a membrane binding protein that modifies the lipid and 
protein environment in the membrane (144, 206), it may possibly recruit Env to viral 
budding sites through interactions with the MSD. This study evaluates the role of the 
hydrophobicity of Env MSD in Env recruitment to HIV-1 viral budding sites.  
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MSD Hydrophobicity does not affect Env recruitment 
In contrast to our expectations, the hydrophobicity of the MSD did not appear to 
play a role in recruitment to viral particles (Figure 5-2A, Figure 5-6 and Figure 5-S1). 
Virion biochemical analysis and the Viral capture assay shows that the Env is 
incorporated into viral particles regardless of the mutation (Figure 5-2B and 3B). Further, 
all the mutant Envs are incorporated to comparable levels (Figure 5-3C, anti GFP (MLV 
Env) capture, infection on 293 TVAs). These data showed that the hydrophobicity of the 
Env is not a necessary factor in its recruitment to viral particles, although the 
hydrophobicity could affect other stages in the Env biogenesis, With the Leucine 
addition/deletion mutants, since the Env is present in viral particles, the only reason for 
its variation of infectivity could be the Env fusogenicity. Indeed, a test of cell-to-cell 
fusogenicity of the different mutant Envs showed that the variation in infectivity mirrored 
the fusion function of the different Envs (Figure 4A).  
 
Helical phasing of Env MSD controls Env function 
Evaluation of gp70 and gp85 in cells showed that removal of Leucines in the 
MSD reduced Env processing (Figure 5-2B) and was deleterious for Env function (Figure 
5-4A). Addition of one or two leucines abolished fusogenicity of Env, while addition of 
three leucines made the Env constitutively fusogenic (Figure 5-4A). These data would be 
consistent with the helical conformation of the Env.  The addition of a single amino acid 
would twist the orientation of the protein with an alpha helix by approximately 103
0
. 
Addition of three or four leucines would effectively introduce one turn of the alpha helix 
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and hence would bring the protein back to the original orientation. However, single 
amino acid increments or decrements in the helix would introduce torsion in the structure 
and this may prevent the normal function of the protein, in this case the F-MLV Env. 
Having seen constitutive fusogenicity of the +3L Env, we considered two possibilities- 1) 
Addition of three leucines would introduce an extra turn of the helix in the MSD, which 
restored the phase of the helix, thus promoting a fusogenic Env trimer; 2) The addition of 
an extra turn of the helix/ three leucines in the MSD could possibly provide a stable 
intermediate for fusion and hence the fusion- restrictive sequences in the CTD are no 
longer required. If the helical torsion determines Env function, then addition of four or 
five leucines in the MSD would make the Env sub-optimal. On the other hand, if three 
extra leucines in the MSD are enough to support a fusogenically active Env, addition of 
further leucines will not affect the infectivity seen with the +3L Env. Infectivity with +4L 
and +5L F-MLV Env pointed that the former hypothesis is true i.e., helical torsion in the 
Env reduces its functional capabilities, and the presence of an extra helical turn in MSD 
alone cannot promote fusogenic activation. 
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Figure 5-1: Schematic of F-MLV Env 
 Sequences in the membrane spanning domain (MSD) and cytoplasmic tail 
domain (CTD) are shown. The leucine rich region that has been modified with leucine 
frameshift mutations has been highlighted. 
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Figure 5-1: Schematic of F-MLV Env 
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Figure 5-2: Hydrophobicity of MSD does not affect Env incorporation in viral 
particles 
(A)Infectivity relative to WT MLV Env of the various mutants are shown. Data 
shown here are an average of at least three experiments. Bars indicate the SD in the 
experiments. (B) 293 FTs transfected with HIV-CMV-GFP and HA tagged Env 
constructs were used in biochemical analyses of cells and viral particles. Representative 
image shows antibody probing against HA (Env) and p24 in cell lysates and viral pellets  
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Figure 5-2: Hydrophobicity of MSD does not affect Env incorporation in viral 
particles 
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Figure 5-3: Infectious viral particle production is not affected by the presence of the 
leucine frameshift mutant F-MLV Envs 
(A) Schematic of the virus capture assay. (B)Infectivity of viral particles 
pseudotyped with the indicated mutant F-MLV Envs and RSV DCTD Env on mCAT-1 
receptor expressing cells are shown. Target cells are added to viral particles captured by 
anti-GFP (MLV Env) antibody (black bars), no antibody (dark grey bars) or untreated 
(light grey bars). (C) Infectivity of viral particles pseudotyped with the indicated mutant 
F-MLV Env and RSV DCTD Env on TVA receptor expressing cells are shown. Data 
shown are an average of 3 experiment. Error bars indicate the SD in the experiments.  
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Figure 5-3: Infectious viral particle production is not affected by the presence of the 
leucine frameshift mutant F-MLV Envs 
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Figure 5-4 Addition/deletion of Leucines in MSD of F-MLV glycoprotein affects 
fusogenecity of Env when the CTD is present 
A)Fusogenecity of the indicated F-MLV FL and R Env mutants, relative to R 
Env is shown as an average of three independent experiments. Bars indicate the SD 
within the experiments. (B) Infectivity of R Envs with the indicated MSD mutations, 
relative to WT Env infectivity is shown. (C) Infectivity of 25 Envs with the indicated 
mutations in the MSD, relative to WT Env infectivity is shown. 
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Figure 5-4: Addition/deletion of Leucines in MSD of F-MLV glycoprotein affects 
fusogenecity of Env when the CTD is present 
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Figure 5-5: Sequences in CTD contributing to infectivity phenotype with 0L and +1L 
Env 
(A) Truncations of CTD and their sequences in the C-terminus are shown. 
Infectivity of the various truncation mutants with WT and +1L Env are shown. Data 
shown are the average of at least 4 experiments. Error bars indicate the SD in the 
experiments. (B) Double alanine mutations in the context of WT and +1L 21 Envs are 
shown. Relative infectivity of the various mutants are shown as indicated. Data shown 
are the average of at least 3 experiments. Error bars indicate the SD in the experiments. 
(C) Single alanine mutations in the context of WT and +1L 21 Envs are shown. 
Infectivity of the various mutants are shown as indicated. Data shown are the average of 
at least 3 experiments. Error bars indicate the SD in the experiments. 
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Figure 5-5: Sequences in CTD contributing to infectivity phenotype with 0L and 
+1L Env 
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Figure 5-6: HIV-1 Env MSD hydrophobicity does not dictate Env recruitment and 
infectivity modulation is independent of the CTD 
Infectivity of HIV-1, relative to WT HIV-1 Env, with the indicated HIV-1 Env 
and its variants are shown as an average of three independent experiments and error bars 
indicate the SD in the experiments.  
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Figure 5-6: HIV-1 Env MSD hydrophobicity does not dictate Env recruitment and 
infectivity modulation is independent of the CTD 
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Figure 5-S1: Infectivity with hydrophobicity change mutants 
Relative infectivity of the indicated F-MLV Env mutants are shown as an average 
of three experiments and the error bars indicate SD in the experiments.  
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Figure 5-S1: Infectivity with hydrophobicity change mutants 
 
 
 
 
 
 
 
 
 
 
 
 
 
162 
 
Figure 5-S2: Infectivity with +4L and +5L mutants 
Relative infectivity of the indicated F-MLV Env mutants are shown as an average 
of three experiments and the error bars indicate SD in the experiments.  
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Figure 5-S2: Infectivity with +4L and +5L mutants 
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Figure 5-S3: +1L MLV Env is specifically recruited to viral budding sites  
293T mCAT-1 cells were transfected with plasmids expressing the HIV Gag 
PTAPAAAA and YFP-tagged +1L MLV Env. The cells were stained with a mouse 
anti- GFP monoclonal antibody and a gold-labelled anti mouse secondary antibody. 
Scanning electron micrographs were obtained for budding virions and back scatter 
detection was employed for labeled Env. Scale bars, 500 nm  
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Figure 5-S3: +1L MLV Env is specifically recruited to viral budding sites  
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VI. Summary and Discussion 
Retroviruses are able to form infectious pseudotyped particles with a variety of 
viral fusion glycoproteins and this Pseudotyping compatibility does not follow family 
lines (121). However, pseudotyping of vector particles allows the targeting of specific 
cell types (12, 65, 95, 134, 181, 213), and this functionality has sparked a lot of interest in 
pseudotyped vectors. As previously mentioned, lentiviral vectors can infect dividing and 
non-dividing cells, leading to long-term stable expression of a transgene in the target cell.  
A combination thereof that possesses lentiviral vector properties and Env that targets it to 
different tissues would be tremendously helpful. The assembly of retroviruses has been 
characterized extensively. But, the mechanisms of Env acquisition have not been 
adequately elucidated. My work has largely shown Vpu as a modulator of specific 
glycoprotein intake into viral particles, and the role of a helical conformation of the Env 
MSD in Env fusogenicity. Also, CTD mutants of the gammaretroviral Env provide 
important clues about the structure of the CTD that is best suited for a native particle 
uptake versus a non-native particle uptake.  
 
Previous work has shown that Vpu prevents incorporation of glycoproteins with 
GaLV Env CTD from coalescing with viral particles (167). Upon an initial observation, 
the GaLV Env CTD did not resemble any known Vpu target. Suspecting a new 
mechanism of Vpu sensitivity for a target protein, mutational analysis was performed on 
the GaLV Env CTD, which led to the characterization of a ‘Vpu sensitivity motif’. This 
motif was also modular, allowing Vpu insensitive proteins to become sensitive. 
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Remarkably, a stringent look of the human glycoproteome reveals the presence of only 
three proteins that bear this sensitivity motif- CD4, a known Vpu target being one of 
them. A slightly broader look shows that several other glycoproteins may be targeted by 
Vpu, by virtue of the presence of an amphipathic alpha helix structure in the CTD of the 
respective Envs.  
 
 The study of Vpu sensitivity on GaLV Env CTD also produced a very valuable 
tool, in that, a library of a Gammaretroviral Env with every position in the CTD mutated, 
was created. Assaying for infectivity of HIV-1 particles with this entire library allowed us 
to determine sequences in the gammaretroviral Env CTD that allow pseudotyping of 
GaLV Env with HIV-1 particles. MLV Env and GaLV Env are closely related as 
mentioned earlier. MLV Env is an extremely well studied Env, with a trove of 
information available about the various domains and the mechanism of Env fusion. 
Comparison of studies performed on MLV Env CTD with the current study involving 
GaLV Env CTD shows that infectivity data in general agree with previously published 
studies. Also, some mutants are infectious with HIV, but not infectious with MLV 
virions, while some other mutants follow the reverse trend. Further studies with such 
mutant Envs will provide valuable clues about mechanism of pseudotyping and 
mechanism of recruitment of Env to different particles.  
 
 GaLV Env is thus a model glycoprotein that is targeted by Vpu and we exploited 
this system to understand further about Vpu sensitivity. Retroviral glycoproteins are 
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trimeric in nature. This trimeric nature allows for trials of trans complementation of Env 
function. Indeed, defective HIV-1 Env and MLV Env has been shown to complement 
each other to form functionally-active, mixed trimers (246, 313-314). Exploiting the 
functional complementation of the MLV Env, we further studied Vpu sensitivity of the 
model Vpu target, GaLV Env CTD. While Env with similar ectodomains have been 
shown to heterotrimerize(41), for the first time, we were able to show that Env trimers 
with different CTDs could efficiently trimerize with each and form a functional Env unit. 
More importantly, the data indicated that Vpu targets a single CTD to enforce its effect 
on the protein. This is an important piece of data to reconcile with, as different 
glycoproteins multimerize and heteromultimerize to varying extents and with this model 
target, we were able to show that Vpu’s effect on one CTD could affect an entire 
complex.  
  
 Further, studies on Vpu using the GaLV Env has given us interesting insights into 
the conformation of the CTD of the gammaretroviral Env itself. Recently cryoelectron-
tomography of the MLV Env has shown that the TM of MLV Env is in a trimeric 
configuration and upon R-peptide cleavage in the Env, the TM legs are splayed. This 
provides a structural basis for fusion activation of the MLV Env in the virus. Our data 
indicates that Vpu targets a single GaLV Env CTD, but only if all the three CTDs of the 
Env are present, indicating that Vpu targets a single helical CTD in a multimer. This 
observation further supports that idea that Env CTD remains a trimer in the cell.  
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 The studies of Vpu sensitivity with GaLV Env CTD has also allowed us to 
develop assays that may potentially be used in inhibitor screens against Vpu. Currently, 
no drugs against Vpu exist. Vpu has been shown to be important for viral pathogenesis in 
the pig-tailed macaque model, as an animal infected with Vpu virus does not progress 
towards AIDS (268). In the presence of Vpu, GaLV Env does not pseudotype with HIV 
particles. However, if Vpu is inhibited or the Vpu-GaLV Env CTD interaction is 
inhibited, then GaLV Env would be able to produce infectious particles with HIV and 
this infectivity can be assayed in a high-throughput format. Exploitation of an observed 
phenotype towards translational research, leading to drug identification is the real benefit 
of this study. 
 
 In addition to screening for inhibitors, an infectivity assay with a CTD based Vpu 
target and an MSD based Vpu target, provided an opportunity to compare the two modes 
and two types of Vpu targeting. Tetherin is targeted by Vpu through the MSD and GaLV 
Env is targeted through its CTD, similar to CD4. Tetherin and CD4 are the most studied 
Vpu target proteins, but use of different assays to study the effect of Vpu on these 
proteins reduces the comparisons that can be made between the two modes of Vpu action. 
Infectivity assays with GaLV Env or with VSV-G in the presence or absence of tetherin 
allows us to compare these two targets directly. While GaLV Env produces infectious 
particles in the absence of Vpu, Tetherin prevents the release of infectious particles in the 
absence of Vpu. Pairwise analysis for infectivity with GaLV Env in the presence or 
absence of Vpu and for VSV-G Env in the presence and absence of tetherin were 
performed to analyse the effect of various mutations in Vpu. Surprisingly, both the 
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targets required the presence of the serines and surrounding amino acids in the hinge 
region of the Vpu CTD, although the subcellular location, where each protein was 
targeted was different. Given the data, further studies on the phosphorylation status of 
Vpu with these mutants have to be performed to understand the differences between the 
two targets.  
 
 The above-mentioned studies indicate the presence of a physical factor, Vpu, 
which prevents the recruitment of a viral or a cellular glycoprotein to HIV budding sites. 
With the next study, we addressed the role of the MSD in MLV Env recruitment to viral 
budding sites. The CTD of MLV Env is not necessary for its specific recruitment to HIV 
virions (168). In the case of HIV-1 Env though, CTD truncated Env mutants are non-
specifically taken up by HIV virions (196). To systematically deduce Env determinants 
of viral pseudotyping, we examined the hydrophobic patch of amino acids in the MLV 
Env MSD. Changes in hydrophobicity of the MSD did not affect Env recruitment to viral 
particles and further did not affect specific localization of Env to budding viruses. 
Surprisingly, addition of three leucines to the MSD of Env partially restored infectivity 
with HIV-1 when compared to WT MLV Env. Such a phenotype is reminiscent of an 
alpha helical structure and indeed, the MSD and CTD of MLV Env is modeled to be a 
continuous alpha helix. Addition of leucines would distort the helix and the fusogenicity 
data with these mutants reflects such a phenotype. 0L R and +3L R Envs are fusogenic 
and all other mutant Envs have varying levels of fusogenicity. Cell-to-cell fusion 
capabilities of these Envs correlates with the infectivity output with these Envs. 
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Truncation of most of the CTD allows partial regain of infectivity and specific sequences 
within the Env CTD regulate this phenotype.  
  
MLV is an Env whose CTD is proteolytically cleaved prior to fusogenic 
activation. A closer look of the HIV Env, which is not proteolytically cleaved during 
fusion activation, revealed a similar phenotyped. Addition of leucines in a stepwise 
fashion decreased infectivity and addition of three leucines partially restored infectivity 
to HIV Env. However, a similar pattern was noted with the CTD Env, indicating that 
the CTD of HIV-1 Env does not regulate components of the Env MSD.   This study 
hence showed the dependence of Env fusogenicity on helical configuration of the Env 
MSD. Through a variety of techniques and methods, we have also shown that the 
hydrophobicity of the MSD of Env does not dictate Env recruitment to virions. 
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VII. Future Directions 
The body of work described in this dissertation provides a basis for further studies 
in several ways. With the creation of a library of gammaretroviral Env CTD mutants, we 
are in possession of a unique tool to understand several aspects of the Env CTD. For 
example, R-peptide cleavage has been reported to be crucial for fusion regulation of the 
MLV Env; But a comprehensive analysis of the Env CTD has not been performed to 
understand Env fusogenicity. Assays with the panel of mutants would allow us to 
genetically tease different sequences required for a particular phenotype attributed to the 
Env CTD.  
   
 The GaLV Env CTD provides an unique opportunity to study Vpu mediated 
effects on a target protein, where the CTD is required for modulation. Potentially, we 
could use GaLV Env as a stand-in model protein fro CD4 to completely understand the 
interaction of Vpu with CD4. Further, the Vpu sensitivity motif may also provide 
information about other host cellular proteins targeted by Vpu. The use of a trimeric 
target protein has helped us understand the action of Vpu on a multimeric target and this 
study may potentially be extended to other monomeric or multimeric proteins that Vpu 
targets. 
 
 The studies on the MSD of Env also provide insights into the fusogenic ability of 
Env. A comprehensive study of fusion maybe performed to understand this phenomenon 
completely. The differences in Envs that are regulated for fusion through proteolytic 
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cleavage of their CTD may be differentiated from those that are not regulated by 
proteolysis of Env CTD. Further work with the MSD mutants may involve understanding 
of the specificity of recruitment of Env to viral particles.  
 
 Progress with retroviral vectors has to match progress with understanding of how 
each component in the vector functions. Mechanisms of pseudotyping would provide an 
understanding of Env acquisition with both the native and non-native viral glycoproteins. 
Such understanding could then lead to creation of vectors that can be targeted to different 
tissues within the body with a high degree of specificity. With these hopes for the future, 
this dissertation is thus concluded.  
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